BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. JAMA Oncol 2018;4:374-8. [PMID: 28975219 DOI: 10.1001/jamaoncol.2017.2925] [Cited by in Crossref: 531] [Cited by in F6Publishing: 574] [Article Influence: 132.8] [Reference Citation Analysis]
Number Citing Articles
1 Haryal A, Townsend MJ, Baskaran V, Srivoleti P, Giobbie-Hurder A, Sack JS, Isidro RA, LeBoeuf NR, Buchbinder EI, Hodi FS, Grover S. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. Cancer 2023;129:367-75. [PMID: 36377339 DOI: 10.1002/cncr.34543] [Reference Citation Analysis]
2 Guan H, Zhou Z, Hou X, Zhang F, Zhao J, Hu K. Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy. Asia Pac J Clin Oncol 2023;19:35-50. [PMID: 35538049 DOI: 10.1111/ajco.13688] [Reference Citation Analysis]
3 Zhao N, Jiang A, Shang X, Zhao F, Wang R, Fu X, Ruan Z, Liang X, Tian T, Yao Y, Li C. Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levels.. [DOI: 10.21203/rs.3.rs-2501974/v1] [Reference Citation Analysis]
4 Zhang Y, Zhu T, Nie R, Lu L, Xiang Z, Xie D, Luo R, Cai M. Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors. JCM 2023;12:736. [DOI: 10.3390/jcm12030736] [Reference Citation Analysis]
5 Peng X, Gong C, Zhang W, Zhou A. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1091088] [Reference Citation Analysis]
6 Nuñez NG, Berner F, Friebel E, Unger S, Wyss N, Gomez JM, Purde MT, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou MT, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto PA, Dummer R, Jäger E, Driessen C, Levesque MP, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (N Y) 2023:S2666-6340(22)00523-2. [PMID: 36693381 DOI: 10.1016/j.medj.2022.12.007] [Reference Citation Analysis]
7 Levi J, Song H. The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. Front Immunol 2022;13:1113924. [PMID: 36700226 DOI: 10.3389/fimmu.2022.1113924] [Reference Citation Analysis]
8 Shalit A, Sarantis P, Koustas E, Trifylli EM, Matthaios D, Karamouzis MV. Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment. Cancers (Basel) 2023;15. [PMID: 36672324 DOI: 10.3390/cancers15020375] [Reference Citation Analysis]
9 Yang F, Shay C, Abousaud M, Tang C, Li Y, Qin Z, Saba NF, Teng Y. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States. J Exp Clin Cancer Res 2023;42:4. [PMID: 36600271 DOI: 10.1186/s13046-022-02568-y] [Reference Citation Analysis]
10 Cai Q, Huo GW, Zhu FY, Yue P, Yuan DQ, Chen P. Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis. Hum Vaccin Immunother 2022;18:2145102. [PMID: 36471629 DOI: 10.1080/21645515.2022.2145102] [Reference Citation Analysis]
11 Knetki-Wróblewska M, Tabor S, Płużański A, Lewandowska Z, Tysarowski A, Pawlik H, Kowalski DM, Krzakowski M. Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer-Data from Daily Practice. Curr Oncol 2022;30:462-75. [PMID: 36661686 DOI: 10.3390/curroncol30010037] [Reference Citation Analysis]
12 Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma. Target Oncol 2022. [PMID: 36571708 DOI: 10.1007/s11523-022-00940-8] [Reference Citation Analysis]
13 Sekikawa M, Sumi T, Ehama Y, Kawamura R, Takeda K, Nagahisa Y, Matsuura K, Watanabe H, Yamada Y, Chiba H. A Non-small Cell Lung Cancer Patient Who Was Successfully Resuscitated After Cardiac Arrest Caused by Infusion-related Reaction with Carboplatin, Paclitaxel, Nivolumab, and Ipilimumab Therapy. JJLC 2022;62:1021-1025. [DOI: 10.2482/haigan.62.1021] [Reference Citation Analysis]
14 Song SJ, Song Y, Jang M, Shin E, Suh SY, Cho YS, Lee J, Oh JM. Prognostic Significance of the Severity of Immune-Related Adverse Events in Advanced Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Real-World Data Analysis. Targ Oncol 2022. [DOI: 10.1007/s11523-022-00936-4] [Reference Citation Analysis]
15 Fujimoto A, Kotake Y, Hisamatsu D, Ookubo N, Yabuuchi Y, Kamimura G, Kai T, Kozono A, Ootsu T, Suzuki H, Matsuo K, Kuwahara K, Oiwane Y, Nagata Y, Tanimoto K, Sato E, Suenaga M, Uehara T, Ikari A, Endo S, Hiraki Y, Kawamata Y. Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: A multicenter retrospective study.. [DOI: 10.21203/rs.3.rs-2355931/v1] [Reference Citation Analysis]
16 Difoum F, Schernberg A, Vanquaethem H, Picchi H, Roy AL, Vuagnat P, Helissey C. Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study. Cancer Reports 2022. [DOI: 10.1002/cnr2.1760] [Reference Citation Analysis]
17 Dercle L, Sun S, Seban R, Mekki A, Sun R, Tselikas L, Hans S, Bernard-tessier A, Mihoubi Bouvier F, Aide N, Vercellino L, Rivas A, Girard A, Mokrane F, Manson G, Houot R, Lopci E, Yeh R, Ammari S, Schwartz LH. Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. Radiology 2022. [DOI: 10.1148/radiol.210518] [Reference Citation Analysis]
18 Pîrlog CF, Paroșanu AI, Slavu CO, Olaru M, Popa AM, Iaciu C, Niță I, Moțatu P, Horia C, Manolescu LSC, Nițipir C. Nivolumab Hypersensitivity Reactions a Myth or Reality in Solid Tumors-A Systematic Review of the Literature. Curr Oncol 2022;29:9428-36. [PMID: 36547155 DOI: 10.3390/curroncol29120741] [Reference Citation Analysis]
19 Hara Y, Baba Y, Toihata T, Harada K, Ogawa K, Iwatsuki M, Iwagami S, Miyamoto Y, Yoshida N, Baba H. Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab. J Gastrointest Oncol 2022;13:2779-88. [PMID: 36636073 DOI: 10.21037/jgo-22-281] [Reference Citation Analysis]
20 Wang Y, Wang Y, Yu J, Meng X. The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues. Cancer Letters 2022;551:215947. [DOI: 10.1016/j.canlet.2022.215947] [Reference Citation Analysis]
21 Bernstein E, Sabari J. Immune-mediated pneumonitis: A clinical conundrum in a patient with stage IV lung adenocarcinoma with a dramatic and durable response to checkpoint inhibitor case report. Current Problems in Cancer: Case Reports 2022;8:100195. [DOI: 10.1016/j.cpccr.2022.100195] [Reference Citation Analysis]
22 Akturk HK, Couts KL, Baschal EE, Karakus KE, Van Gulick RJ, Turner JA, Pyle L, Robinson WA, Michels AW. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma. JAMA Netw Open 2022;5:e2246400. [DOI: 10.1001/jamanetworkopen.2022.46400] [Reference Citation Analysis]
23 Yoshikawa Y, Imamura M, Yamauchi M, Hayes CN, Aikata H, Okamoto W, Miyata Y, Okada M, Hattori N, Sugiyama K, Yoshioka Y, Toratani S, Takechi M, Ichinohe T, Ueda T, Takeno S, Kobayashi T, Ohdan H, Teishima J, Hide M, Nagata Y, Kudo Y, Iida K, Chayama K. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors. BMC Cancer 2022;22:1232. [PMID: 36447159 DOI: 10.1186/s12885-022-10327-7] [Reference Citation Analysis]
24 Hamano H, Miyata K, Hara T, Sakaguchi S, Oura M, Niimura T, Aizawa F, Yagi K, Okada N, Miki H, Goda M, Ishizawa-izawa Y, Zamami Y, Yanagawa H, Ishizawa K. Multiple Adverse Events of anti-PD1/PDL1 Therapy: A Case- control Study using a Japanese Prescription-diagnostics Database.. [DOI: 10.21203/rs.3.rs-2268880/v1] [Reference Citation Analysis]
25 Wu L, Xu Y, Wang X, Cheng X, Zhang Y, Wang Y, Fan X, Zhao H, Liu H, Chai X, Zhang L, Wang M, Li N, Pan H, Lian X. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.. [DOI: 10.21203/rs.3.rs-2210602/v1] [Reference Citation Analysis]
26 Dey A, Austin M, Kluger HM, Trunova N, Mann H, Shire N, Morgan C, Zhou D, Mugundu GM. Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1026964] [Reference Citation Analysis]
27 Takeda Y, Kusaba Y, Tsukita Y, Uemura Y, Miyauchi E, Yamamoto T, Mayahara H, Hata A, Nakayama H, Tanaka S, Uchida J, Usui K, Toyoda T, Tamiya M, Morimoto M, Oya Y, Kodaira T, Jingu K, Sugiura H. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study. Clinical and Translational Radiation Oncology 2022;37:57-63. [DOI: 10.1016/j.ctro.2022.08.010] [Reference Citation Analysis]
28 Goto Y, Yoh K, Kato T, Hosomi Y, Usui K, Fukui T, Hirano K, Tanaka H, Taguri M, Kunitoh H. Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer. Japanese Journal of Clinical Oncology 2022. [DOI: 10.1093/jjco/hyac159] [Reference Citation Analysis]
29 Gao Y, Wu C, Chen X, Ma L, Zhang X, Chen J, Liao X, Liu M. PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy. Front Immunol 2022;13:1049043. [DOI: 10.3389/fimmu.2022.1049043] [Reference Citation Analysis]
30 Iwahori K, Uenami T, Yano Y, Ueda T, Tone M, Naito Y, Suga Y, Fukushima K, Shiroyama T, Miyake K, Koyama S, Hirata H, Nagatomo I, Kida H, Mori M, Takeda Y, Kumanogoh A, Wada H. Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients. Sci Rep 2022;12:17461. [PMID: 36261600 DOI: 10.1038/s41598-022-22356-0] [Reference Citation Analysis]
31 Hata H, Matsumura C, Chisaki Y, Nishioka K, Tokuda M, Miyagi K, Suizu T, Yano Y. A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors. Cancer Control 2022;29:10732748221130576. [PMID: 36254804 DOI: 10.1177/10732748221130576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Taniguchi Y, Shimokawa T, Takiguchi Y, Misumi T, Nakamura Y, Kawashima Y, Furuya N, Shiraishi Y, Harada T, Tanaka H, Miura S, Uchiyama A, Nakahara Y, Tokito T, Naoki K, Bessho A, Goto Y, Seike M, Okamoto H. A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630. Clin Cancer Res 2022;28:4402-9. [PMID: 35980349 DOI: 10.1158/1078-0432.CCR-22-1687] [Reference Citation Analysis]
33 Wu Y, Li D, Wu M, Yang Y, Shen M, Chen K. Peripheral absolute eosinophil count identifies the risk of serious immune-related adverse events in non-small cell lung cancer. Front Oncol 2022;12:1004663. [DOI: 10.3389/fonc.2022.1004663] [Reference Citation Analysis]
34 Murayama M, Hosonuma M, Kuramasu A, Yoshimura K. Current Status of Immune Checkpoint Inhibitors in the Broncho-Esophagological Field. The Journal of the Japan Broncho-esophagological Society 2022;73:308-317. [DOI: 10.2468/jbes.73.308] [Reference Citation Analysis]
35 Kurokawa K, Mitsuishi Y, Shimada N, Kawakami Y, Miura K, Miyawaki T, Asao T, Ko R, Shukuya T, Shibayama R, Nojiri S, Takahashi K. Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study. BMC Cancer 2022;22:1047. [PMID: 36203123 DOI: 10.1186/s12885-022-10133-1] [Reference Citation Analysis]
36 Qin W, Yang L, Fan B, Zou B, Duan Y, Li B, Wang L. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer. Front Immunol 2022;13:931429. [DOI: 10.3389/fimmu.2022.931429] [Reference Citation Analysis]
37 Li Y, Niu L. Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review. Sci Rep 2022;12:16040. [PMID: 36163484 DOI: 10.1038/s41598-022-20040-x] [Reference Citation Analysis]
38 Kapoor A, Noronha V, Patil VM, Joshi A, Menon N, Kumar A, Mahajan A, Janu A, Kumar R, Prabhash K. Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors. South Asian J Cancer. [DOI: 10.1055/s-0041-1740243] [Reference Citation Analysis]
39 Mari R, Guerin M, Vicier C, Walz J, Bonnet N, Pignot G, Gravis G. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report. Front Immunol 2022;13:984132. [DOI: 10.3389/fimmu.2022.984132] [Reference Citation Analysis]
40 Yin N, Liu X, Ye X, Song W, Lu J, Chen X. PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review. Front Oncol 2022;12:961266. [DOI: 10.3389/fonc.2022.961266] [Reference Citation Analysis]
41 Tsuji M, Hayashi N. An Exploratory Cross-sectional Study of Immune Checkpoint Inhibitors and Immuno-related Adverse Events: Knowledge and Influencing Factors among Japanese Oncology Nurses. Asia-Pacific Journal of Oncology Nursing 2022. [DOI: 10.1016/j.apjon.2022.100147] [Reference Citation Analysis]
42 Akazawa Y, Yoshikawa A, Kanazu M, Yano Y, Yamaguchi T, Mori M. Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study. Thorac Cancer 2022;13:2450-8. [PMID: 35820673 DOI: 10.1111/1759-7714.14576] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Terashi N, Hisakane K, Miyadera K, Kato Y, Terashima Y, Suzuki A, Atsumi K, Seike M, Gemma A, Hirose T. A Case of Fulminant Type 1 Diabetes Mellitus After the Administration of Durvalumab for Small-cell Lung Cancer. JJLC 2022;62:323-328. [DOI: 10.2482/haigan.62.323] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Hao Y, Zhang X, Yu L. Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. Front Oncol 2022;12:911906. [DOI: 10.3389/fonc.2022.911906] [Reference Citation Analysis]
45 Gosangi B, McIntosh L, Keraliya A, Irugu DVK, Baheti A, Khandelwal A, Thomas R, Braschi-Amirfarzan M. Imaging features of toxicities associated with immune checkpoint inhibitors. Eur J Radiol Open 2022;9:100434. [PMID: 35967881 DOI: 10.1016/j.ejro.2022.100434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Guezour N, Soussi G, Brosseau S, Abbar B, Naltet C, Vauchier C, Poté N, Hachon L, Namour C, Khalil A, Trédaniel J, Zalcman G, Gounant V. Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study. Cancers 2022;14:3878. [DOI: 10.3390/cancers14163878] [Reference Citation Analysis]
47 Kfoury M, Najean M, Lappara A, Voisin AL, Champiat S, Michot JM, Laghouati S, Robert C, Besse B, Soria JC, Lambotte O, Massard C, Marabelle A, Texier M. Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. Cancer Treat Rev 2022;110:102452. [PMID: 35998515 DOI: 10.1016/j.ctrv.2022.102452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Izutani Y, Ushimaru Y, Nishikawa K, Kawabata R, Ohara N, Miyake Y, Maeda S, Nakahira S, Nakata K, Miyamoto A, Yasuhara Y. A Case of Unresectable Advanced Esophageal Cancer with Tuberculosis and Immune Thrombocytopenic Purpura Due to Nivolumab. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2022;55:483-490. [DOI: 10.5833/jjgs.2021.0138] [Reference Citation Analysis]
49 Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, Huang AC, Muselman A, Manne S, Kuthuru O, Staupe RP, Adamski SA, Kannan S, Kurupati RK, Ertl HCJ, Wong JL, Bournazos S, McGettigan S, Schuchter LM, Kotecha RR, Funt SA, Voss MH, Motzer RJ, Lee CH, Bajorin DF, Mitchell TC, Ravetch JV, Wherry EJ. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nat Immunol 2022;23:1183-92. [PMID: 35902637 DOI: 10.1038/s41590-022-01274-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
50 Ma Y, Ma X, Wang J, Wu S, Wang J, Cao B. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis. World J Surg Oncol 2022;20:242. [PMID: 35897018 DOI: 10.1186/s12957-022-02695-y] [Reference Citation Analysis]
51 Higashiyama RI, Horinouchi H, Kuchiba A, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients. J Cancer Res Clin Oncol 2022. [PMID: 35900471 DOI: 10.1007/s00432-022-04205-9] [Reference Citation Analysis]
52 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
53 Wu K, Xia B, Zhang J, Li X, Yang S, Zhang M, Zhu L, Wang B, Xu X, Ma S, Chen X. Positive Correlation of Peripheral CD8+ T Lymphocytes with Immune-Related Adverse Events and Combinational Prognostic Value in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers 2022;14:3568. [DOI: 10.3390/cancers14153568] [Reference Citation Analysis]
54 Katakura S, Murakami S. Clinically-meaningful improvements in therapy for unresectable NSCLC. Expert Rev Anticancer Ther 2022. [PMID: 35838638 DOI: 10.1080/14737140.2022.2102483] [Reference Citation Analysis]
55 Chye A, Allen I, Barnet M, Burnett DL. Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. Front Oncol 2022;12:894015. [DOI: 10.3389/fonc.2022.894015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Ortega-Franco A, Hodgson C, Raja H, Carter M, Lindsay C, Hughes S, Cove-Smith L, Taylor P, Summers Y, Blackhall F, Califano R. Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. Target Oncol 2022. [PMID: 35781861 DOI: 10.1007/s11523-022-00889-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Chen Y, Zhuang L, Zhang D, Du X, Sheng L, Cui D. Thyroid Dysfunction as a Predictive Indicator in Camrelizumab of Advanced Esophageal Squamous Cell Carcinoma. Journal of Immunology Research 2022;2022:1-8. [DOI: 10.1155/2022/4015897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Morimoto K, Yamada T, Morimoto Y, Ishikawa T, Asai J, Fujihara A, Arai A, Katoh N, Ukimura O, Hirano S, Itoh Y, Takayama K. A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors. International Immunopharmacology 2022;108:108775. [DOI: 10.1016/j.intimp.2022.108775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Pluye M, Gouraud A, Herve M, Le H, Dagonneau T, Dalle S, Cottin J, Cucherat M, Atzenhoffer M. Adverse drug reactions associated with immune checkpoint inhibitors: An exploratory nested case-control study in a historical cohort. Therapies 2022. [DOI: 10.1016/j.therap.2022.07.001] [Reference Citation Analysis]
60 Robles-alonso V, Martínez-valle F, Borruel N. Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management. Front Med 2022;9:906098. [DOI: 10.3389/fmed.2022.906098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Hibino M, Uryu K, Takeda T, Kunimatsu Y, Shiotsu S, Uchino J, Hirai S, Yamada T, Okada A, Hasegawa Y, Hiranuma O, Chihara Y, Kamada R, Tobe S, Maeda K, Horiuchi S, Kondo T, Takayama K. Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan. J Thorac Oncol 2022:S1556-0864(22)00295-7. [PMID: 35752437 DOI: 10.1016/j.jtho.2022.05.015] [Reference Citation Analysis]
62 Li L, Chen T, Lai H, Zhang A, Zhao X, Wu J, Hong H, Wu L, Lin S, Wang K, Zhang H, Fang C. Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy. Medicine (Baltimore) 2022;101:e29336. [PMID: 35687776 DOI: 10.1097/MD.0000000000029336] [Reference Citation Analysis]
63 Kanabar SS, Tiwari A, Soran V, Balendran P, Price M, Turner AM. Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. Thorax 2022:thoraxjnl-2020-215614. [PMID: 35688624 DOI: 10.1136/thoraxjnl-2020-215614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Hung YT, Chung WH, Huang YL, Chen CB. Immune checkpoint inhibitor-associated panniculitis: clinicopathological features and cytokine profiles. J Eur Acad Dermatol Venereol 2022. [PMID: 35686625 DOI: 10.1111/jdv.18312] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Iranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-illescas D, Pardo N, Navarro A, Martinez-marti A, Cedres S, Carbonell C, Frigola J, Amat R, Felip E. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front Med 2022;9:875974. [DOI: 10.3389/fmed.2022.875974] [Reference Citation Analysis]
66 Magdelaine P, Costantini A, Fabre L, Giroux-Leprieur E. Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report. Thorac Cancer 2022. [PMID: 35615894 DOI: 10.1111/1759-7714.14405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Muir CA, Tsang VHM, Menzies AM, Clifton-bligh RJ. Immune Related Adverse Events of the Thyroid – A Narrative Review. Front Endocrinol 2022;13:886930. [DOI: 10.3389/fendo.2022.886930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Tatar G, Alçin G, Sengul Samanci N, Erol Fenercioglu Ö, Beyhan E, Cermik TF. Diagnostic impact of 18F-FDG PET/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy. Clin Transl Oncol 2022. [PMID: 35594002 DOI: 10.1007/s12094-022-02840-9] [Reference Citation Analysis]
69 Fuu T, Iijima K, Kusama Y, Otsuki T, Kato H. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report. J Med Case Rep 2022;16:193. [PMID: 35581611 DOI: 10.1186/s13256-022-03426-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Zhang RY, Zhu SJ, Xue P, He SQ. Cutaneous metastasis from esophageal squamous cell carcinoma: A case report. World J Clin Cases 2022; 10(14): 4676-4683 [DOI: 10.12998/wjcc.v10.i14.4676] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Léger M, Routy B, Juneau D. FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. Seminars in Nuclear Medicine 2022. [DOI: 10.1053/j.semnuclmed.2022.04.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Kotwal A, Mcleod DS. Thyroid Dysfunction from Treatments for Solid Organ Cancers. Endocrinology and Metabolism Clinics of North America 2022. [DOI: 10.1016/j.ecl.2021.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Harada M, Tamura S, Miura A, Komori H, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab. CMAR 2022;Volume 14:1641-51. [DOI: 10.2147/cmar.s360473] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Gärtner F, Aßmus J, Fløtten Ø, Ramnefjell MP, Aanerud M. Characteristics and survival of patients with non-small cell lung cancer treated with immune-checkpoint inhibitors in the real-world: experiences from Bergen, Norway. Acta Oncol 2022;:1-5. [PMID: 35481424 DOI: 10.1080/0284186X.2022.2068969] [Reference Citation Analysis]
75 Foster CC, Seiwert TY. Reply to "Guarantee-time bias in studies on the relationship between immune-related adverse events and antitumor activity". Cancer 2022. [PMID: 35452138 DOI: 10.1002/cncr.34242] [Reference Citation Analysis]
76 Zhong X, Ying J, Liao H, Shen L, Pan Y. Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors. Future Oncol 2022;18:2289-300. [PMID: 35440175 DOI: 10.2217/fon-2021-1537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Ishido K, Tanabe S, Katada C, Ishibashi Y, Kitahara G, Onoue M, Kubota Y, Furue Y, Wada T, Watanabe A, Kusano C. Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab. J Gastrointest Canc. [DOI: 10.1007/s12029-022-00823-1] [Reference Citation Analysis]
78 Machairas N, Tsilimigras DI, Pawlik TM. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. Cancers 2022;14:2018. [DOI: 10.3390/cancers14082018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
79 Wang H, Zhou F, Zhao C, Cheng L, Zhou C, Qiao M, Li X, Chen X. Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy. Front Immunol 2022;13:840313. [PMID: 35222434 DOI: 10.3389/fimmu.2022.840313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
80 Valencia Soto CM, Villacañas Palomares MV, Garcia-Avello Fernández-Cueto A, Barbadillo Villanueva S, Martínez Callejo V, Ochagavía Sufrategui M, Muñoz Cacho P, Valero Domínguez M. Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer. Eur J Hosp Pharm 2022:ejhpharm-2021-003038. [PMID: 35383033 DOI: 10.1136/ejhpharm-2021-003038] [Reference Citation Analysis]
81 Lopci E, Hicks RJ, Dimitrakopoulou-strauss A, Dercle L, Iravani A, Seban RD, Sachpekidis C, Humbert O, Gheysens O, Glaudemans AWJM, Weber W, Wahl RL, Scott AM, Pandit-taskar N, Aide N. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05780-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
82 Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Yonezawa H, Araki Y, Morinaga S, Saito S, Sone T, Kasahara K, Tsuchiya H. The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer. Front Oncol 2022;12:871675. [DOI: 10.3389/fonc.2022.871675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
83 Serino M, Freitas C, Martins M, Ferreira P, Cardoso C, Veiga F, Santos V, Araújo D, Novais-bastos H, Magalhães A, Queiroga H, Fernandes G, Hespanhol V. Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors. Pulmonology 2022. [DOI: 10.1016/j.pulmoe.2022.03.003] [Reference Citation Analysis]
84 Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. J Immunother Cancer 2022;10. [PMID: 35354588 DOI: 10.1136/jitc-2021-004421] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
85 Manson G, Lemchukwu AC, Mokrane FZ, Lopci E, Aide N, Vercellino L, Houot R, Dercle L. Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors. Eur Radiol 2022. [PMID: 35344061 DOI: 10.1007/s00330-022-08669-8] [Reference Citation Analysis]
86 Paschou SA, Liontos M, Eleftherakis-papaiakovou E, Stefanaki K, Markellos C, Koutsoukos K, Zagouri F, Psaltopoulou T, Dimopoulos M. Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. Front Oncol 2022;12:847917. [DOI: 10.3389/fonc.2022.847917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Ohe Y, Yamazaki N, Yamamoto N, Murakami H, Yoh K, Kitano S, Hashimoto H, Murayama A, Nakane S, Gemma A. The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study. Jpn J Clin Oncol 2022:hyac024. [PMID: 35325169 DOI: 10.1093/jjco/hyac024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Yin J, Wen M, Cheng J, Hu L, Yang L, Chang X, Zhou Z, Li H, Liu Y, Li J. A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen. Front Med (Lausanne) 2022;9:712466. [PMID: 35265635 DOI: 10.3389/fmed.2022.712466] [Reference Citation Analysis]
89 Kondo Y, Akahira J, Morosawa T, Toi Y, Endo A, Satio H, Endo M, Sugawara S, Tanaka Y. Anti-nuclear antibody and a granuloma could be biomarkers for iCIs-related hepatitis by anti-PD-1 treatment. Sci Rep 2022;12:3669. [PMID: 35256688 DOI: 10.1038/s41598-022-07770-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Adda L, Batteux B, Saidak Z, Poulet C, Arnault J, Chauffert B, Séjourné A. Effets indésirables rhumatologiques associés aux inhibiteurs de points de contrôle immunitaire : impact sur la survie globale. Revue du Rhumatisme 2022;89:168-175. [DOI: 10.1016/j.rhum.2021.10.564] [Reference Citation Analysis]
91 McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, Balaji AK, Vetizou M, Prescott SM, Fernandes MR, Costa RGF, Yuan W, Salcedo R, Bahadiroglu E, Roy S, DeBlasio RN, Morrison RM, Chauvin JM, Ding Q, Zidi B, Lowin A, Chakka S, Gao W, Pagliano O, Ernst SJ, Rose A, Newman NK, Morgun A, Zarour HM, Trinchieri G, Dzutsev AK. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat Med 2022. [PMID: 35228752 DOI: 10.1038/s41591-022-01698-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 23.0] [Reference Citation Analysis]
92 Kopecký J, Kubeček O, Kyllarová A, Priester P. Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma. Onkologie 2022;16:10-15. [DOI: 10.36290/xon.2022.002] [Reference Citation Analysis]
93 Kodama S, Yoshida M, Miki H, Ito T, Goto H, Terashima T, Fujiwara A, Hayashi K, Kamon T. A Case of Myocarditis-combined Myasthenia Gravis After Combination Therapy with Ipilimumab and Nivolumab for Pleomorphic Carcinoma of the Lung. JJLC 2022;62:57-64. [DOI: 10.2482/haigan.62.57] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Kaneoka A, Okada E, Sugino H, Saito-sasaki N, Omoto D, Nakamura M. Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis. Diagnostics 2022;12:480. [DOI: 10.3390/diagnostics12020480] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Vincent MP, Navidzadeh JO, Bobbala S, Scott EA. Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. Cancer Cell 2022:S1535-6108(22)00008-3. [PMID: 35148814 DOI: 10.1016/j.ccell.2022.01.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
96 Scheiner B, Pinter M. Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab. memo 2022;15:58-61. [DOI: 10.1007/s12254-021-00747-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Sonehara K, Tateishi K, Araki T, Komatsu M, Akahane J, Yamamoto H, Hanaoka M. Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. CMAR 2022;Volume 14:427-35. [DOI: 10.2147/cmar.s347852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Jing Y, Yang J, Johnson DB, Moslehi JJ, Han L. Harnessing big data to characterize immune-related adverse events. Nat Rev Clin Oncol 2022. [PMID: 35039679 DOI: 10.1038/s41571-021-00597-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
99 Cheung YM, Wang W, McGregor B, Hamnvik OR. Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother 2022. [PMID: 35022907 DOI: 10.1007/s00262-021-03128-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
100 Hsiehchen D, Naqash AR, Espinoza M, Von Itzstein MS, Cortellini A, Ricciuti B, Owen DH, Laharwal M, Toi Y, Burke M, Xie Y, Gerber DE. Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology 2022;11:2017162. [PMID: 35003896 DOI: 10.1080/2162402X.2021.2017162] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
101 Mori T, Tanaka H, Deguchi S, Yamakoshi Y, Miki Y, Yoshii M, Tamura T, Toyokawa T, Lee S, Muguruma K, Ohira M. Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer. PLoS ONE 2022;17:e0262455. [DOI: 10.1371/journal.pone.0262455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Spagnoletti A, Platania M, Brambilla M, Occhipinti M, Canziani L, Cabras A, Provenzano L, Leone AG, Ambrosini P, Prelaj A. Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease. Tumori 2022;:3008916211067565. [PMID: 34989254 DOI: 10.1177/03008916211067565] [Reference Citation Analysis]
103 Takahara Y, Tanaka T, Ishige Y, Shionoya I, Yamamura K, Sakuma T, Nishiki K, Nakase K, Nojiri M, Kato R, Shinomiya S, Fujimoto Y, Oikawa T, Mizuno S. Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer. Thorac Cancer 2022. [PMID: 34989146 DOI: 10.1111/1759-7714.14309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Sano A, Sohda M, Nakazawa N, Ubukata Y, Kuriyama K, Kimura A, Kogure N, Hosaka H, Naganuma A, Sekiguchi M, Saito K, Ogata K, Sakai M, Ogawa H, Shirabe K, Saeki H. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study. BMC Cancer 2022;22:22. [PMID: 34980017 DOI: 10.1186/s12885-021-09118-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Humbert O, Bauckneht M, Gal J, Paquet M, Chardin D, Rener D, Schiazza A, Genova C, Schiappa R, Zullo L, Rossi G, Martin N, Hugonnet F, Darcourt J, Morbelli S, Otto J. Prognostic value of immunotherapy-induced organ inflammation assessed on (18)FDG PET in patients with metastatic non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2022;49:3878-91. [PMID: 35562529 DOI: 10.1007/s00259-022-05788-8] [Reference Citation Analysis]
106 Rengarajan M, Faje A. Anti-neoplastic Immunomodulatory Treatments and the Pituitary. Pituitary Disorders throughout the Life Cycle 2022. [DOI: 10.1007/978-3-030-99918-6_25] [Reference Citation Analysis]
107 López-mora DA, Carrió I, Flotats A. Nuclear Medicine in the Assessment of Adverse Effects of Cancer Therapy in the Lung, Kidney, Gastrointestinal Tract, and Central Nervous System. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_30-2] [Reference Citation Analysis]
108 Endo S, Honda T, Kawahara T, Sakakibara R, Mitsumura T, Okamoto T, Miyazaki Y. Profile of metastatic lung cancer patients susceptible to development of thromboembolism during immunotherapy. Cancer Treatment and Research Communications 2022;31:100547. [DOI: 10.1016/j.ctarc.2022.100547] [Reference Citation Analysis]
109 López-mora DA, Carrió I, Flotats A. Nuclear Medicine in the Assessment of Adverse Effects of Cancer Therapy in the Lung, Kidney, Gastrointestinal Tract, and Central Nervous System. Nuclear Oncology 2022. [DOI: 10.1007/978-3-031-05494-5_30] [Reference Citation Analysis]
110 Naganuma K, Horita Y, Matsuo K, Miyama Y, Mihara Y, Yasuda M, Nakano S, Hamaguchi T. An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer. Intern Med . [DOI: 10.2169/internalmedicine.9161-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Xu B, Cheng H, Li K, Lv Y, Zeng X, Liu T, Yu W, Guo W. Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study. J Cancer Res Clin Oncol 2022. [PMID: 34973080 DOI: 10.1007/s00432-021-03873-3] [Reference Citation Analysis]
112 Kotwal A, Rouleau SG, Dasari S, Kottschade L, Ryder M, Kudva YC, Markovic S, Erickson D. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort. J Investig Med 2021:jim-2021-002099. [PMID: 34969937 DOI: 10.1136/jim-2021-002099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Sonehara K, Tateishi K, Araki T, Komatsu M, Akahane J, Yamamoto H, Hanaoka M. Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series. Case Rep Oncol 2021;14:1561-6. [PMID: 34949996 DOI: 10.1159/000519597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Usui Y, Sasada S, Kirita K, Watanabe S, Tsuchiya Y, Nakamura M. A Case of Lung Adenocarcinoma Responding to Ramucirumab and Docetaxel After Rapid Tumor Growth Following Pembrolizumab Treatment. JJLC 2021;61:970-974. [DOI: 10.2482/haigan.61.970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
115 Cortijo-Cascajares S, Cercós-Lletí AC, Ortiz-Pérez S, Caro-Teller JM, Ferrari-Piquero JM. Analysis of immune-mediated reactions in patients with non-small cell lung cancer treated with nivolumab and its association with effectiveness. J Oncol Pharm Pract 2021;:10781552211067429. [PMID: 34907812 DOI: 10.1177/10781552211067429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Bastacky ML, Wang H, Fortman D, Rahman Z, Mascara GP, Brenner T, Najjar YG, Luke JJ, Kirkwood JM, Zarour HM, Davar D. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. Front Oncol 2021;11:749064. [PMID: 34900695 DOI: 10.3389/fonc.2021.749064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
117 Cheng K, Wang Y, Zhou Y, Xia R, Tang L, Liu J. Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development. Clin Med Insights Oncol 2021;15:11795549211056261. [PMID: 34866959 DOI: 10.1177/11795549211056261] [Reference Citation Analysis]
118 Luo W, Wang Z, Zhang T, Yang L, Xian J, Li Y, Li W. Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. Precision Clinical Medicine 2021;4:258-70. [DOI: 10.1093/pcmedi/pbab027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
119 Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, Hatta T, Yogo N, Yasuda S, Toyoda H, Abe T, Kawashima H, Hashimoto N, Fujishiro M. Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancer Invest 2021;:1-10. [PMID: 34658277 DOI: 10.1080/07357907.2021.1994586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
120 Zou XL, Chen WY, Zhang GY, Ke H, Yang QH, Li XB. Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors. Front Pharmacol 2021;12:747075. [PMID: 34819857 DOI: 10.3389/fphar.2021.747075] [Reference Citation Analysis]
121 Ogiwara T, Kawazoe H, Egami S, Hashimoto H, Saito Y, Sakiyama N, Ohe Y, Yamaguchi M, Furukawa T, Hara A, Hiraga Y, Jibiki A, Yokoyama Y, Suzuki S, Nakamura T. Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study. Front Oncol 2021;11:770268. [PMID: 34820333 DOI: 10.3389/fonc.2021.770268] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Bilger G, Girard N, Doubre H, Levra MG, Giroux-Leprieur E, Giraud F, Decroisette C, Carton M, Massiani MA. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study. Cancer Immunol Immunother 2021. [PMID: 34821950 DOI: 10.1007/s00262-021-03114-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
123 Wang W, Gu X, Wang L, Pu X, Feng H, Xu C, Lou G, Shao L, Xu Y, Wang Q, Wang S, Gao W, Zhang Y, Song Z. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study. Cancer Immunol Immunother 2021. [PMID: 34817639 DOI: 10.1007/s00262-021-03115-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
124 Yoneda H, Nokihara H, Mitsuhashi A, Ozaki R, Yabuki Y, Ogino H, Otsuka K, Nishioka Y. Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma. BMC Pulm Med 2021;21:373. [PMID: 34781910 DOI: 10.1186/s12890-021-01746-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Lopci E. Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. J Clin Med 2021;10:5160. [PMID: 34768681 DOI: 10.3390/jcm10215160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
126 Percik R, Liel Y, Urban D, Bar J, Ben-Ami E, Abu Tailakh M. Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database. Acta Oncol 2021;60:1466-71. [PMID: 34379562 DOI: 10.1080/0284186X.2021.1958006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 Kostine M, Mauric E, Tison A, Barnetche T, Barre A, Nikolski M, Rouxel L, Dutriaux C, Dousset L, Prey S, Beylot-Barry M, Seneschal J, Veillon R, Vergnenegre C, Daste A, Domblides C, Sionneau B, Gross-Goupil M, Ravaud A, Forcade E, Schaeverbeke T; FHU ACRONIM. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer 2021;157:474-84. [PMID: 34649118 DOI: 10.1016/j.ejca.2021.08.036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
128 Ichimura T, Hinata M, Ichikura D, Suzuki S. Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study. Cancer Chemother Pharmacol 2021. [PMID: 34648059 DOI: 10.1007/s00280-021-04362-7] [Reference Citation Analysis]
129 Halle BR, Betof Warner A, Zaman FY, Haydon A, Bhave P, Dewan AK, Ye F, Irlmeier R, Mehta P, Kurtansky NR, Lacouture ME, Hassel JC, Choi JS, Sosman JA, Chandra S, Otto TS, Sullivan R, Mooradian MJ, Chen ST, Dimitriou F, Long G, Carlino M, Menzies A, Johnson DB, Rotemberg VM. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J Immunother Cancer 2021;9:e003066. [PMID: 34635495 DOI: 10.1136/jitc-2021-003066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
130 Fujisaki T, Watanabe S, Ota T, Kushiro K, Sato Y, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Matsumoto N, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events. Front Oncol 2021;11:704475. [PMID: 34631533 DOI: 10.3389/fonc.2021.704475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Cano-Cruz LG, Barrera-Vargas A, Mateos-Soria A, Soto-Perez-de-Celis E, Merayo-Chalico J. Rheumatological Immune-related Adverse Events of Checkpoints Inhibitors: a Narrative Review for the Latin American Rheumatologist. Arch Med Res 2021:S0188-4409(21)00193-4. [PMID: 34649738 DOI: 10.1016/j.arcmed.2021.09.004] [Reference Citation Analysis]
132 Nishimura A, Ono A, Wakuda K, Kawabata T, Yabe M, Miyawaki T, Miyawaki E, Kodama H, Nishioka N, Mamesaya N, Kobayashi H, Omori S, Kenmotsu H, Naito T, Murakami H, Harada H, Takahashi T. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer. Invest New Drugs 2021. [PMID: 34633575 DOI: 10.1007/s10637-021-01191-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
133 Kato M, Mori M, Miura K, Asao T, Motomura H, Nishino K, Ko R, Koyama R, Hayashi T, Takahashi K. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report. Thorac Cancer 2021;12:3076-9. [PMID: 34617405 DOI: 10.1111/1759-7714.14185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
134 Zhao Z, Wang X, Qu J, Zuo W, Tang Y, Zhu H, Chen X. Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:708195. [PMID: 34604047 DOI: 10.3389/fonc.2021.708195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
135 Lee S, Shim HS, Ahn BC, Lim SM, Kim HR, Cho BC, Hong MH. Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience. Cancer Immunol Immunother 2021. [PMID: 34568975 DOI: 10.1007/s00262-021-03052-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
136 Deng C, Yang M, Jiang H, Wang R, Yang Z, Sun H, Cui H. Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report. Front Oncol 2021;11:664809. [PMID: 34540659 DOI: 10.3389/fonc.2021.664809] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
137 Foster CC, Couey MA, Kochanny SE, Khattri A, Acharya RK, Tan YC, Brisson RJ, Leidner RS, Seiwert TY. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer 2021. [PMID: 34547103 DOI: 10.1002/cncr.33780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
138 Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Fujimoto Y, Hibi H, Sone M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer 2020;8:e000779. [PMID: 32606047 DOI: 10.1136/jitc-2020-000779] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
139 Fujiwara N, Watanabe M, Katayama A, Noda Y, Eguchi J, Kataoka H, Kagawa S, Wada J. Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor-induced diabetes mellitus: A report of two cases. Clin Case Rep 2021;9:e04574. [PMID: 34522382 DOI: 10.1002/ccr3.4574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
140 Kelly K, Manitz J, Patel MR, D'Angelo SP, Apolo AB, Rajan A, Kasturi V, Speit I, Bajars M, Warth J, Gulley JL. Efficacy and immune-related adverse event associations in avelumab-treated patients. J Immunother Cancer 2020;8:e001427. [PMID: 33219092 DOI: 10.1136/jitc-2020-001427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
141 Sibille A, Henket M, Corhay JL, Alfieri R, Louis R, Duysinx B. White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer. Lung 2021;199:549-57. [PMID: 34518898 DOI: 10.1007/s00408-021-00474-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
142 Ferrari C, Santo G, Merenda N, Branca A, Mammucci P, Pizzutilo P, Gadaleta CD, Rubini G. Immune Checkpoint Inhibitors in Advanced NSCLC: [18F]FDG PET/CT as a Troubleshooter in Treatment Response. Diagnostics (Basel) 2021;11:1681. [PMID: 34574022 DOI: 10.3390/diagnostics11091681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 Pinato DJ, Marron TU, Mishra-Kalyani PS, Gong Y, Wei G, Szafron D, Sharon E, Saeed A, Jun T, Dharmapuri S, Naqash AR, Peeraphatdit T, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, D'Alessio A, Kaseb AO, Huang YH, Ang C, Schneider J, Pillai A, Rimassa L, Goldberg KB, Pazdur R, Theoret M, Lemery S, Fashoyin-Aje ', Cortellini A, Pelosof L. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer 2021;157:140-52. [PMID: 34508996 DOI: 10.1016/j.ejca.2021.08.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
144 Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. J Cancer Res Clin Oncol 2021. [PMID: 34510271 DOI: 10.1007/s00432-021-03782-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
145 Li X, Qu LX, Ren YM, Hu C. Case Report: A Case Report and Literature Review on Severe Bullous Skin Reaction Induced by anti-PD-1 Immunotherapy in a Cervical Cancer Patient. Front Pharmacol 2021;12:707967. [PMID: 34504425 DOI: 10.3389/fphar.2021.707967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
146 Thompson LL, Krasnow NA, Chang MS, Yoon J, Li EB, Polyakov NJ, Molina GE, Said JT, Huang K, Kuchroo JR, Hinton AN, Reynolds KL, Chen ST. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer. JAMA Dermatol 2021;157:577-82. [PMID: 33760001 DOI: 10.1001/jamadermatol.2021.0326] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
147 Rabeau A, Lavesque J, Joseph C, Cortot A, Mazières J. Questions pratiques en immunothérapie dans le cancer bronchique non à petites cellules : dose, durée, rythme de traitement, réintroduction. Revue des Maladies Respiratoires Actualités 2021;13:2S164-2S173. [DOI: 10.1016/s1877-1203(21)00108-7] [Reference Citation Analysis]
148 Ny L, Jespersen H, Karlsson J, Alsén S, Filges S, All-Eriksson C, Andersson B, Carneiro A, Helgadottir H, Levin M, Ljuslinder I, Olofsson Bagge R, Sah VR, Stierner U, Ståhlberg A, Ullenhag G, Nilsson LM, Nilsson JA. The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. Nat Commun 2021;12:5155. [PMID: 34453044 DOI: 10.1038/s41467-021-25332-w] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 16.0] [Reference Citation Analysis]
149 Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, Yildiz VO, Smith SA, Buck B, Haddad D, Gumina R, William BM, Penza S, Saad A, Denlinger N, Vallakati A, Baliga R, Benza R, Binkley P, Wei L, Mocarski M, Devine SM, Jaglowski S, Addison D. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. J Immunother Cancer 2021;9:e002303. [PMID: 34429331 DOI: 10.1136/jitc-2020-002303] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
150 Sato Y, Watanabe S, Ota T, Kushiro K, Fujisaki T, Takahashi M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Hokari S, Kondo R, Hayashi M, Ishikawa H, Miyabayashi T, Abe T, Miura S, Tanaka H, Okajima M, Terada M, Ishida T, Iwashima A, Sato K, Yoshizawa H, Aoki N, Ohshima Y, Koya T, Kikuchi T. Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease. Transl Lung Cancer Res 2021;10:3132-43. [PMID: 34430353 DOI: 10.21037/tlcr-21-198] [Reference Citation Analysis]
151 Estenaga A, Rodriguez-Garijo N, Tomás-Velázquez A, Antoñanzas-Pérez J, Alvarez-Gigli ML, García-Tobar L, Espaa-Alonso A, Salido-Vallejo R. Immunotherapy-intensified paraneoplastic dermatomyositis. Indian J Dermatol Venereol Leprol 2021;:1-4. [PMID: 34491672 DOI: 10.25259/IJDVL_1306_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
152 Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A, Shinomiya S, Imai H, Kobayashi K, Kagamu H. Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs. J Clin Med 2021;10:3744. [PMID: 34442054 DOI: 10.3390/jcm10163744] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
153 Gohara K, Okazaki A, Takeda Y, Iwasa K, Shibata K. Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports. Respir Med Case Rep 2021;33:101469. [PMID: 34401305 DOI: 10.1016/j.rmcr.2021.101469] [Reference Citation Analysis]
154 Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Hanai N, Muro K, Hida T. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. BMC Cancer 2021;21:924. [PMID: 34399710 DOI: 10.1186/s12885-021-08661-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
155 Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188615. [PMID: 34403771 DOI: 10.1016/j.bbcan.2021.188615] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 10.5] [Reference Citation Analysis]
156 Spyrou N, Vallianou N, Kadillari J, Dalamaga M. The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era. Seminars in Cancer Biology 2021;73:356-76. [DOI: 10.1016/j.semcancer.2021.05.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
157 Zhu H, Ivanovic M, Nguyen A, Nguyen PK, Wu SM. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. J Mol Cell Cardiol 2021;160:121-7. [PMID: 34303670 DOI: 10.1016/j.yjmcc.2021.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
158 Wang M, Zhai X, Li J, Guan J, Xu S, Li Y, Zhu H. The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. Front Immunol 2021;12:670391. [PMID: 34367136 DOI: 10.3389/fimmu.2021.670391] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
159 Hao L, Hu Y, Hu J, Liu Y, Mao B, Chen H, Gong X, Wang D, Wang L, Wang D. Case Report: A Squamous Cell Lung Carcinoma Patient Who Responded to Neoadjuvant Immunochemotherapy but Died From Anastomosis Leakage or/and irAEs: Immune Microenvironment and Genomic Features Changes. Front Oncol 2021;11:674328. [PMID: 34367960 DOI: 10.3389/fonc.2021.674328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
160 Kotwal A, Ryder M. Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers. Curr Opin Endocrinol Diabetes Obes 2021;28:517-24. [PMID: 34269714 DOI: 10.1097/MED.0000000000000664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
161 Alexander JL, Ibraheim H, Sheth B, Little J, Khan MS, Richards C, Hunter N, Chauhan D, Ratnakumaran R, McHugh K, Pinato DJ, Nathan P, Choy J, Crusz SM, Furness A, Turajlic S, Pickering L, Larkin J, Teare JP, Papa S, Speight A, Sharma A, Powell N. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. J Immunother Cancer 2021;9:e002742. [PMID: 34233964 DOI: 10.1136/jitc-2021-002742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
162 Siwicki M, Gort-Freitas NA, Messemaker M, Bill R, Gungabeesoon J, Engblom C, Zilionis R, Garris C, Gerhard GM, Kohl A, Lin Y, Zou AE, Cianciaruso C, Bolli E, Pfirschke C, Lin YJ, Piot C, Mindur JE, Talele N, Kohler RH, Iwamoto Y, Mino-Kenudson M, Pai SI, deVito C, Koessler T, Merkler D, Coukos A, Wicky A, Fraga M, Sempoux C, Jain RK, Dietrich PY, Michielin O, Weissleder R, Klein AM, Pittet MJ. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy. Sci Immunol 2021;6:eabi7083. [PMID: 34215680 DOI: 10.1126/sciimmunol.abi7083] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
163 Komo T, Suzuki T, Tazawa H, Sada H, Morimoto H, Shimada N, Hadano N, Onoe T, Sudo T, Shimizu Y, Tashiro H. Clinical complete response after nivolumab administered as a third-line treatment for unresectable advanced gastric cancer with peritoneal dissemination: A case report. Int J Surg Case Rep 2021;84:106161. [PMID: 34237686 DOI: 10.1016/j.ijscr.2021.106161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
164 Booka E, Kikuchi H, Haneda R, Soneda W, Kawata S, Murakami T, Matsumoto T, Hiramatsu Y, Takeuchi H. Impact of Immune-related Adverse Events on Nivolumab Efficacy in Patients With Upper Gastrointestinal Cancer. In Vivo 2021;35:2321-6. [PMID: 34182512 DOI: 10.21873/invivo.12506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Grimaud F, Penaranda G, Stavris C, Retornaz F, Brunel V, Cailleres S, Pegliasco H, Le Treut J, Grisoni V, Coquet E, Chiche L, Rognon A. Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach. Ther Clin Risk Manag 2021;17:669-77. [PMID: 34234443 DOI: 10.2147/TCRM.S308194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
166 Callejo A, Frigola J, Iranzo P, Carbonell C, Diaz N, Marmolejo D, Assaf JD, Cedrés S, Martinez-Marti A, Navarro A, Pardo N, Amat R, Felip E. Interrelations between Patients' Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients. Cancers (Basel) 2021;13:3249. [PMID: 34209601 DOI: 10.3390/cancers13133249] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
167 Daniello L, Elshiaty M, Bozorgmehr F, Kuon J, Kazdal D, Schindler H, Shah R, Volckmar AL, Lusky F, Diekmann L, Liersch S, Faehling M, Muley T, Kriegsmann M, Benesova K, Stenzinger A, Thomas M, Christopoulos P. Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Front Oncol 2021;11:703893. [PMID: 34268127 DOI: 10.3389/fonc.2021.703893] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
168 Ye L, Ariyapperuma M, Jacques A, Meniawy T, Millward M. Hospitalizations in solid tumor phase I clinical trial patients: Incidence, pattern and clinical outcomes at an Australian phase I clinical trial unit. Asia Pac J Clin Oncol 2021. [PMID: 34180591 DOI: 10.1111/ajco.13622] [Reference Citation Analysis]
169 Fujimoto A, Toyokawa G, Koutake Y, Kimura S, Kawamata Y, Fukuishi K, Yamazaki K, Takeo S. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer 2021;12:2198-204. [PMID: 34173724 DOI: 10.1111/1759-7714.14063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
170 Desharnais L, Walsh LA, Quail DF. Exploiting the obesity-associated immune microenvironment for cancer therapeutics. Pharmacol Ther 2021;:107923. [PMID: 34171329 DOI: 10.1016/j.pharmthera.2021.107923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Puzanov I, Subramanian P, Yatsynovich YV, Jacobs DM, Chilbert MR, Sharma UC, Ito F, Feuerstein SG, Stefanovic F, Switzer B, Hicar MD, Curtis AB, Spangenthal EJ, Dy GK, Ernstoff MS, Vachhani P, Page BJ, Agrawal N, Khunger A, Kapoor A, Hattoum A, Jerome SJ. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. J Immunother Cancer 2021;9:e002553. [PMID: 34162715 DOI: 10.1136/jitc-2021-002553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
172 Ikeda T, Ishihara H, Nemoto Y, Tachibana H, Fukuda H, Yoshida K, Takagi T, Iizuka J, Hashimoto Y, Ishida H, Kondo T, Tanabe K. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Urol Oncol 2021:S1078-1439(21)00218-0. [PMID: 34172370 DOI: 10.1016/j.urolonc.2021.05.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
173 Yamashita S, Mitsumura T, Suzuki T, Sakakibara R, Honda T, Miyazaki Y. A Case of Pulmonary Adenocarcinoma Continuously Treated with Immune Checkpoint Inhibitor Despite Repeated Checkpoint Inhibitor Pneumonitis. JJLC 2021;61:201-207. [DOI: 10.2482/haigan.61.201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
174 Ando T, Ueda A, Ogawa K, Motoo I, Kajiura S, Nakajima T, Hirano K, Okumura T, Tsukada K, Hara T, Suzuki N, Nakada N, Horikawa N, Fujii T, Yasuda I. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis. In Vivo 2021;35:475-82. [PMID: 33402499 DOI: 10.21873/invivo.12281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
175 Gong J, Drobni ZD, Zafar A, Quinaglia T, Hartmann S, Gilman HK, Raghu VK, Gongora C, Sise ME, Alvi RM, Zubiri L, Nohria A, Sullivan R, Reynolds KL, Zlotoff D, Neilan TG. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer 2021;9:e002771. [PMID: 34145031 DOI: 10.1136/jitc-2021-002771] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
176 Kobayashi K, Iikura Y, Hiraide M, Yokokawa T, Aoyama T, Shikibu S, Hashimoto K, Suzuki K, Sato H, Sugiyama E, Tajima M, Hama T. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma. In Vivo 2020;34:2647-52. [DOI: 10.21873/invivo.12083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
177 Ono K, Ono H, Toi Y, Sugisaka J, Aso M, Saito R, Kawana S, Aiba T, Odaka T, Matsuda S, Saito S, Narumi A, Ogasawara T, Shimizu H, Domeki Y, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer. Cancer Med 2021;10:4796-804. [PMID: 34121358 DOI: 10.1002/cam4.4045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
178 Vetrei C, Passariello M, Froechlich G, Rapuano Lembo R, Zambrano N, De Lorenzo C. Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. Cancers (Basel) 2021;13:2858. [PMID: 34201082 DOI: 10.3390/cancers13122858] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
179 Suzuki K, Terakawa T, Furukawa J, Harada K, Hinata N, Nakano Y, Fujisawa M. Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma. J Immunother 2020;43:38-42. [PMID: 31567704 DOI: 10.1097/CJI.0000000000000299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
180 Frelau A, Jali E, Campillo-Gimenez B, Pracht M, Porneuf M, Dinulescu M, Edeline J, Boussemart L, Lesimple T. Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies. Melanoma Res 2021;31:208-17. [PMID: 33904517 DOI: 10.1097/CMR.0000000000000739] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
181 Holstead RG, Kartolo BA, Hopman WM, Baetz TD. Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors. Melanoma Res 2021;31:258-63. [PMID: 33904518 DOI: 10.1097/CMR.0000000000000736] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
182 Li Y, Zhang Y, Jia X, Jiang P, Mao Z, Liang T, Du Y, Zhang J, Zhang G, Niu G, Guo H. Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis. Clin Lung Cancer 2021:S1525-7304(21)00098-X. [PMID: 34183265 DOI: 10.1016/j.cllc.2021.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
183 Zhao D, Li H, Mambetsariev I, Chen C, Pharaon R, Fricke J, Baroz AR, Kulkarni P, Xing Y, Massarelli E, Koczywas M, Reckamp KL, Margolin K, Salgia R. Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:2653. [PMID: 34071259 DOI: 10.3390/cancers13112653] [Reference Citation Analysis]
184 Egami S, Kawazoe H, Hashimoto H, Uozumi R, Arami T, Sakiyama N, Ohe Y, Nakada H, Aomori T, Ikemura S, Fukunaga K, Yamaguchi M, Nakamura T. Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study. Front Oncol 2021;11:618570. [PMID: 34123782 DOI: 10.3389/fonc.2021.618570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
185 To KKW, Fong W, Cho WCS. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. Front Oncol 2021;11:635007. [PMID: 34113560 DOI: 10.3389/fonc.2021.635007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 14.5] [Reference Citation Analysis]
186 Narita T, Hatakeyama S, Numakura K, Kobayashi M, Muto Y, Saito M, Narita S, Tanaka T, Noro D, Tokui N, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C. Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study. Int J Urol 2021;28:899-905. [PMID: 34028105 DOI: 10.1111/iju.14601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
187 Criscitiello C, Corti C, Pravettoni G, Curigliano G. Managing side effects of immune checkpoint inhibitors in breast cancer. Crit Rev Oncol Hematol 2021;162:103354. [PMID: 34029683 DOI: 10.1016/j.critrevonc.2021.103354] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
188 Thompson L, Li E, Krasnow N, Chang M, Said J, Molina G, Polyakov N, Yoon J, Dee E, Huang K, Blum A, Kuchroo J, Hinton A, Reynolds K, Chen S. Effect of dermatological consultation on survival in patients with checkpoint inhibitor‐associated cutaneous toxicity. Br J Dermatol 2021;185:627-35. [DOI: 10.1111/bjd.20074] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
189 Abid MB. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations. J Immunother Cancer 2021;9:e002307. [PMID: 33931473 DOI: 10.1136/jitc-2020-002307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
190 Bruyère CL, Souquet PJ, Dalle S, Corbaux P, Boespflug A, Duruisseaux M, Kiakouama-Maleka L, Reverdy T, Maugeais M, Sahin G, Maillet D, Péron J. Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes. Cancers (Basel) 2021;13:2365. [PMID: 34068892 DOI: 10.3390/cancers13102365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
191 Kuo IY, Yang YE, Yang PS, Tsai YJ, Tzeng HT, Cheng HC, Kuo WT, Su WC, Chang CP, Wang YC. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. Theranostics 2021;11:7029-44. [PMID: 34093869 DOI: 10.7150/thno.60040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
192 Mizukami K, Sakata Y, Seo K, Kitamoto S, Mura T, Kikkawa A, Hiraki K. Multicenter Joint Retrospective Study on the Onset of Immune-related Adverse Events by TPS in Patients Indicated for Non-small Cell Lung Cancer Pembrolizumab Monotherapy. Jpn J Pharm Health Care Sci 2021;47:239-249. [DOI: 10.5649/jjphcs.47.239] [Reference Citation Analysis]
193 Bai R, Li L, Chen X, Chen N, Song W, Zhang Y, Lv Z, Han F, Zhao Y, Li W, Cui J. Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors. J Oncol 2021;2021:9935076. [PMID: 34335763 DOI: 10.1155/2021/9935076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
194 Shukla N, Hanna N, Durm G. Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC. JCO Oncol Pract 2021;17:472-4. [PMID: 33939474 DOI: 10.1200/OP.21.00059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
195 Collet L, Delrieu L, Bouhamama A, Crochet H, Swalduz A, Nerot A, Marchal T, Chabaud S, Heudel PE. Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort. Cancers (Basel) 2021;13:2200. [PMID: 34063692 DOI: 10.3390/cancers13092200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
196 Sakamoto A, Funamizu N, Iwata M, Nagaoka T, Tamura K, Sakamoto K, Takai A, Ogawa K, Takada Y. Acute-onset type 1 diabetes mellitus developing after administration of pembrolizumab: a case report. Journal of the Japan Pancreas Society 2021;36:158-162. [DOI: 10.2958/suizo.36.158] [Reference Citation Analysis]
197 Kita T, Araya T, Sakai T, Uchida Y, Matsuoka H, Kasahara K. Nivolumab-Induced Polymyalgia Rheumatica in a Patient with Lung Adenocarcinoma. Am J Med Sci 2021;362:321-3. [PMID: 33905737 DOI: 10.1016/j.amjms.2021.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
198 Oyanagi J, Koh Y, Sato K, Teraoka S, Tokudome N, Hayata A, Akamatsu H, Ozawa Y, Nakanishi M, Ueda H, Yamamoto N. Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors. Clin Lung Cancer 2021:S1525-7304(21)00091-7. [PMID: 34049821 DOI: 10.1016/j.cllc.2021.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Hata H, Mio T, Yamashita D, Matsumura C, Chisaki Y, Motohashi H, Yano Y. Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey. Cancer Control 2020;27:1073274820977200. [PMID: 33297768 DOI: 10.1177/1073274820977200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
200 Tingry T, Massy E, Piperno M, Auroux M, Kostine M, Maillet D, Amini-Adle M, Fabien N, Estublier C, Goncalves D, Girard N, Confavreux CB. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)]. Bull Cancer 2021;108:643-53. [PMID: 33902919 DOI: 10.1016/j.bulcan.2021.01.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
201 Lu L, Xing K, Wei W, Ling Y, Li P, Li S, Wang Y, Xie D, Guo R, Cai M. Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma. Int J Cancer 2021. [PMID: 33890283 DOI: 10.1002/ijc.33609] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
202 Shimozaki K, Sukawa Y, Sato Y, Horie S, Chida A, Tsugaru K, Togasaki K, Kawasaki K, Hirata K, Hayashi H, Hamamoto Y, Kanai T. Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. Future Oncol 2021;17:2593-603. [PMID: 33878916 DOI: 10.2217/fon-2020-0861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
203 Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 2021:dgab263. [PMID: 33878162 DOI: 10.1210/clinem/dgab263] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
204 Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Yokoi T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Haratani K, Teraoka S, Tokito T, Murakami S, Tamiya A, Itoh S, Yokouchi H, Watanabe S, Yamaguchi O, Tomii K, Yamamoto N. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. Eur J Cancer 2021;150:63-72. [PMID: 33892408 DOI: 10.1016/j.ejca.2021.03.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
205 El Hazzaz R, Kfoury M, Lavaud P, Marabelle A, Champiat S, Mellas N, Besse B, Massard C, Geraud A. [Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors]. Bull Cancer 2021;108:635-42. [PMID: 33888298 DOI: 10.1016/j.bulcan.2021.01.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Peiffert M, Cugnet-Anceau C, Dalle S, Chikh K, Assaad S, Disse E, Raverot G, Borson-Chazot F, Abeillon-du Payrat J. Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). Cancers (Basel) 2021;13:1944. [PMID: 33920721 DOI: 10.3390/cancers13081944] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
207 Duclos V, Iep A, Gomez L, Goldfarb L, Besson FL. PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. Int J Mol Sci 2021;22:4159. [PMID: 33923839 DOI: 10.3390/ijms22084159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
208 Portenkirchner C, Kienle P, Horisberger K. Checkpoint Inhibitor-Induced Colitis-A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. Pharmaceuticals (Basel) 2021;14:367. [PMID: 33923423 DOI: 10.3390/ph14040367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
209 Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y, Hao Y, Zhang Z. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. Front Oncol 2021;11:633032. [PMID: 33912454 DOI: 10.3389/fonc.2021.633032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
210 Hirata A, Saraya T, Kobayashi F, Noda A, Aso K, Sakuma S, Kurokawa N, Inoue M, Mikura S, Oda M, Ishida M, Honda K, Nakamoto K, Tamura M, Takata S, Ishii H, Takizawa H. Immune-related adverse events with immune checkpoint inhibitors: Special reference to the effects on the lungs. Medicine (Baltimore) 2021;100:e25275. [PMID: 33832093 DOI: 10.1097/MD.0000000000025275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
211 Indini A, Rijavec E, Grossi F. Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review. Cancers (Basel) 2021;13:1794. [PMID: 33918661 DOI: 10.3390/cancers13081794] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
212 Yamaguchi H, Miyoshi Y, Uehara Y, Fujii K, Nagata S, Obata Y, Kosugi M, Hazama Y, Yasuda T. Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma. Diabetol Int 2021;12:234-40. [PMID: 33786278 DOI: 10.1007/s13340-020-00459-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
213 Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Matsumoto H, Hirano K, Kominami R, Tomii K, Suzuki H, Hirashima T, Tanaka S, Uchida J, Morita M, Kanazu M, Mori M, Nagata K, Fukuda I, Tamiya M. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study. BMC Cancer 2021;21:346. [PMID: 33794809 DOI: 10.1186/s12885-021-08048-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
214 Zhang S, Pease DF, Kulkarni AA, Kumar M, Shanley RM, Xu B, Joshi SP, Patel MR. Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer. Clin Med Insights Oncol 2021;15:11795549211004489. [PMID: 34248362 DOI: 10.1177/11795549211004489] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
215 Giustini N, Bazhenova L. Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs). Lung Cancer (Auckl) 2021;12:21-34. [PMID: 33790679 DOI: 10.2147/LCTT.S235102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
216 Eze C, Schmidt-Hegemann NS, Sawicki LM, Kirchner J, Roengvoraphoj O, Käsmann L, Mittlmeier LM, Kunz WG, Tufman A, Dinkel J, Ricke J, Belka C, Manapov F, Unterrainer M. PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions. Eur J Nucl Med Mol Imaging 2021. [PMID: 33760957 DOI: 10.1007/s00259-021-05211-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
217 Griewing LM, Schweizer C, Schubert P, Rutzner S, Eckstein M, Frey B, Haderlein M, Weissmann T, Semrau S, Gostian AO, Müller SK, Traxdorf M, Iro H, Zhou JG, Gaipl US, Fietkau R, Hecht M. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. BMC Cancer 2021;21:314. [PMID: 33761922 DOI: 10.1186/s12885-021-08006-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
218 Thomas QD, Sinoquet L, Maraver A, Quantin X. Dissociated response related to corticosteroids in lung cancer treated by immunotherapy: A case report. Clin Case Rep 2021;9:e03973. [PMID: 34026127 DOI: 10.1002/ccr3.3973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
219 Morimoto K, Yamada T, Takumi C, Ogura Y, Takeda T, Onoi K, Chihara Y, Taniguchi R, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K. Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study. Front Oncol 2021;11:630136. [PMID: 33833990 DOI: 10.3389/fonc.2021.630136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
220 Le TK, Kaul S, Cappelli LC, Naidoo J, Semenov YR, Kwatra SG. Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. J Dermatolog Treat 2021;:1-5. [PMID: 33656965 DOI: 10.1080/09546634.2021.1898529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
221 Tasaka Y, Honda T, Nishiyama N, Tsutsui T, Saito H, Watabe H, Shimaya K, Mochizuki A, Tsuyuki S, Kawahara T, Sakakibara R, Mitsumura T, Okamoto T, Kobayashi M, Chiaki T, Yamashita T, Tsukada Y, Taki R, Jin Y, Sakashita H, Natsume I, Saitou K, Miyashita Y, Miyazaki Y. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. Lung Cancer 2021;155:120-6. [PMID: 33798901 DOI: 10.1016/j.lungcan.2021.03.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
222 Wang X, Niu X, An N, Sun Y, Chen Z. Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer. Front Oncol 2021;11:611012. [PMID: 33816241 DOI: 10.3389/fonc.2021.611012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
223 Cramer-van der Welle CM, Verschueren MV, Tonn M, Peters BJM, Schramel FMNH, Klungel OH, Groen HJM, van de Garde EMW; Santeon NSCLC Study Group. Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. Sci Rep 2021;11:6306. [PMID: 33737641 DOI: 10.1038/s41598-021-85696-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
224 Umehara K, Yama K, Goto K, Wakamoto A, Hatsuyama T, Honjo O, Saikai T, Fujita A, Sato H. Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer. Cancer Control 2021;28:1073274820985790. [PMID: 33733906 DOI: 10.1177/1073274820985790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Thompson LL, Chang MS, Polyakov NJ, Blum AE, Josephs N, Krasnow NA, Yoon J, Li EB, Molina GE, Said JT, Huang K, Kuchroo JR, Hinton AN, Chen ST. Prognostic significance of cutaneous immune-related adverse events in patients with melanoma and other cancers on immune checkpoint inhibitors. J Am Acad Dermatol 2021:S0190-9622(21)00563-6. [PMID: 33722547 DOI: 10.1016/j.jaad.2021.03.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
226 Ye W, Olsson-Brown A, Watson RA, Cheung VTF, Morgan RD, Nassiri I, Cooper R, Taylor CA, Akbani U, Brain O, Matin RN, Coupe N, Middleton MR, Coles M, Sacco JJ, Payne MJ, Fairfax BP. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. Br J Cancer 2021;124:1661-9. [PMID: 33723392 DOI: 10.1038/s41416-021-01310-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
227 Wu C, Zhong L, Wu Q, Lin S, Xie X. The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases. Immunotherapy 2021;13:527-39. [PMID: 33715386 DOI: 10.2217/imt-2020-0230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
228 Isono T, Kagiyama N, Shibata S, Nakajima H, Matsui Y, Takano K, Nishida T, Hosoda C, Kawate E, Kobayashi Y, Ishiguro T, Takaku Y, Kurashima K, Yanagisawa T, Takayanagi N. A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer. Thorac Cancer 2021;12:1387-97. [PMID: 33710764 DOI: 10.1111/1759-7714.13915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
229 Roopkumar J, Swaidani S, Kim AS, Thapa B, Gervaso L, Hobbs BP, Wei W, Alban TJ, Funchain P, Kundu S, Sangwan N, Rayman P, Pavicic PG Jr, Diaz-Montero CM, Barnard J, McCrae KR, Khorana AA. Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. Med (N Y) 2021;2:423-34. [PMID: 34036293 DOI: 10.1016/j.medj.2021.02.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
230 Shibata Y, Murakami S, Kato T. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. Expert Opin Drug Saf 2021;20:537-47. [PMID: 33650443 DOI: 10.1080/14740338.2021.1898584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Jing Y, Zhang Y, Wang J, Li K, Chen X, Heng J, Gao Q, Ye Y, Zhang Z, Liu Y, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. J Natl Cancer Inst 2021:djab035. [PMID: 33705549 DOI: 10.1093/jnci/djab035] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
232 Nakahara Y, Matsutani T, Igarashi Y, Matsuo N, Himuro H, Saito H, Yamada K, Murotani K, Hoshino T, Azuma K, Sasada T. Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody. Cancer Immunol Immunother 2021;70:2881-92. [PMID: 33751180 DOI: 10.1007/s00262-021-02900-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
233 Chen AY, Wolchok JD, Bass AR. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol 2021;17:213-23. [PMID: 33686279 DOI: 10.1038/s41584-021-00584-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 18.0] [Reference Citation Analysis]
234 Chen X, Nie J, Dai L, Hu W, Zhang J, Han J, Ma X, Tian G, Han S, Wu D, Wang Y, Long J, Zhang Z, Fang J. Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. Front Oncol 2021;11:607531. [PMID: 33747922 DOI: 10.3389/fonc.2021.607531] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
235 Hisanaga K, Uchino H, Kakisu N, Miyagi M, Yoshikawa F, Sato G, Isobe K, Kishi K, Homma S, Hirose T. Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan. Diabetes Metab Syndr Obes 2021;14:773-81. [PMID: 33654416 DOI: 10.2147/DMSO.S289446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
236 Marron TU, Ryan AE, Reddy SM, Kaczanowska S, Younis RH, Thakkar D, Zhang J, Bartkowiak T, Howard R, Anderson KG, Olson D, Naqash AR, Patel RB, Sachdev E, Rodriguez-Ruiz ME, Sheffer M, Church S, Fuhrman C, Overacre-Delgoffe A, Nguyen R, Florou V, Thaxton JE, Aggen DH, Guerriero JL. Considerations for treatment duration in responders to immune checkpoint inhibitors. J Immunother Cancer 2021;9:e001901. [PMID: 33653801 DOI: 10.1136/jitc-2020-001901] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]
237 Simó-Perdigó M, Vercher-Conejero JL, Viteri S, García-Velloso MJ. Immunotherapy, cancer and PET. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:123-35. [PMID: 33674234 DOI: 10.1016/j.remn.2021.02.001] [Reference Citation Analysis]
238 Gounant V, Duruisseaux M, Soussi G, Van Hulst S, Bylicki O, Cadranel J, Wislez M, Trédaniel J, Spano JP, Helissey C, Chouaid C, Molinier O, Dhalluin X, Doucet L, Hureaux J, Cazes A, Zalcman G. Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients. Cancers (Basel) 2021;13:1040. [PMID: 33801285 DOI: 10.3390/cancers13051040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
239 Simó-perdigó M, Vercher-conejero J, Viteri S, García-velloso M. Immunotherapy, cancer and PET. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2021;40:123-135. [DOI: 10.1016/j.remnie.2021.02.003] [Reference Citation Analysis]
240 Wang D, Chen C, Gu Y, Lu W, Zhan P, Liu H, Lv T, Song Y, Zhang F. Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis. Front Oncol 2021;11:631949. [PMID: 33732650 DOI: 10.3389/fonc.2021.631949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
241 Freitas C, Jacob M, Tavares N, Cruz-Martins N, Souto-Moura C, Araújo D, Novais-Bastos H, Santos V, Fernandes G, Magalhães A, Hespanhol V, Queiroga H. Modified Glasgow Prognostic Score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents. Anticancer Drugs 2021;32:567-74. [PMID: 33661189 DOI: 10.1097/CAD.0000000000001060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
242 Thompson LL, Nadelmann ER, Blum AE, Yoon J, Polyakov NJ, Kagan RD, Gainor JF, Mooradian MJ, Chen ST. Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer. Eur J Cancer 2021;147:13-6. [PMID: 33607381 DOI: 10.1016/j.ejca.2021.01.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
243 Paderi A, Giorgione R, Giommoni E, Mela MM, Rossi V, Doni L, Minervini A, Carini M, Pillozzi S, Antonuzzo L. Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:860. [PMID: 33670634 DOI: 10.3390/cancers13040860] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
244 Egami S, Kawazoe H, Hashimoto H, Uozumi R, Arami T, Sakiyama N, Ohe Y, Nakada H, Aomori T, Ikemura S, Fukunaga K, Yamaguchi M, Nakamura T. Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study. J Cancer 2021;12:2105-12. [PMID: 33754009 DOI: 10.7150/jca.53242] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
245 Ravasio S. Industrial Perspective on Immunotherapy. Adv Exp Med Biol 2021;1295:327-47. [PMID: 33543467 DOI: 10.1007/978-3-030-58174-9_15] [Reference Citation Analysis]
246 Zhong L, Wu Q, Chen F, Liu J, Xie X. Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:2559-76. [PMID: 33576872 DOI: 10.1007/s00262-020-02803-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
247 Li Y, Lv M, Liu J, Ma J, Liang M, Zheng N. The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/PD-L1 Therapy for Lung Cancer: A Bibliometric Analysis. Cancer Manag Res 2021;13:1383-93. [PMID: 33613031 DOI: 10.2147/CMAR.S270099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
248 Shahzad O, Thompson N, Clare G, Welsh S, Damato E, Corrie P. Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm. Ther Adv Med Oncol 2021;13:1758835921992989. [PMID: 33633802 DOI: 10.1177/1758835921992989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
249 Lui DTW, Lee CH, Tang V, Fong CHY, Lee ACH, Chiu JWY, Leung RCY, Kwok GGW, Li BCW, Cheung TT, Woo YC, Lam KSL, Yau T. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes. Endocr Pract 2021:S1530-891X(21)00030-6. [PMID: 33581327 DOI: 10.1016/j.eprac.2021.01.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
250 Iafolla MAJ, Yang C, Chandran V, Pintilie M, Li Q, Bedard PL, Hansen A, Lheureux S, Spreafico A, Razak AA, Hakgor S, Giesler A, Pugh TJ, Siu LL. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. JNCI Cancer Spectr 2021;5:pkaa115. [PMID: 33554038 DOI: 10.1093/jncics/pkaa115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
251 Ferrara R, Campochiaro C, Garassino MC. Shifting From a “One Size Fits All” to a Tailored Approach for Immune-Related Adverse Events. Journal of Thoracic Oncology 2021;16:183-6. [DOI: 10.1016/j.jtho.2020.11.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
252 Park JH, You GL, Ahn MJ, Kim SW, Hong MH, Han JY, Ock CY, Lee JS, Oh IJ, Lee SY, Kim CH, Min YJ, Choi YH, Ryu JS, Park SH, Ahn HK, Shim BY, Lee KH, Lee SY, Kim JS, Yi J, Choi SK, An H, Kang JH. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05. J Cancer Res Clin Oncol 2021;147:2459-69. [PMID: 33523301 DOI: 10.1007/s00432-021-03527-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Jeurling S, Cappelli LC. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis. Curr Opin Rheumatol 2020;32:315-20. [PMID: 32168068 DOI: 10.1097/BOR.0000000000000701] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
254 Tyan K, Baginska J, Brainard M, Giobbie-hurder A, Severgnini M, Manos M, Haq R, Buchbinder EI, Ott PA, Hodi FS, Rahma OE. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:2209-21. [DOI: 10.1007/s00262-021-02855-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
255 Kono Y, Choda Y, Nakagawa M, Miyahara K, Ishida M, Kubota T, Seo K, Hirata T, Obayashi Y, Gotoda T, Moritou Y, Okikawa Y, Iwamoto Y, Okada H. Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab. Target Oncol 2021;16:237-48. [PMID: 33475927 DOI: 10.1007/s11523-021-00790-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
256 Rose LM, DeBerg HA, Vishnu P, Frankel JK, Manjunath AB, Flores JPE, Aboulafia DM. Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors. Front Oncol 2020;10:570752. [PMID: 33520695 DOI: 10.3389/fonc.2020.570752] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
257 Matsukane R, Watanabe H, Minami H, Hata K, Suetsugu K, Tsuji T, Masuda S, Okamoto I, Nakagawa T, Ito T, Eto M, Mori M, Nakanishi Y, Egashira N. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. Sci Rep 2021;11:1324. [PMID: 33446685 DOI: 10.1038/s41598-020-79397-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
258 Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raoof S, Rubin GD, Powell C, Inoue Y, Hatabu H. Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. Radiology 2021;298:550-66. [PMID: 33434111 DOI: 10.1148/radiol.2021203427] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
259 Xu H, Xu X, Ge W, Lei J, Cao D. The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis. Ther Adv Med Oncol 2020;12:1758835920980546. [PMID: 33425028 DOI: 10.1177/1758835920980546] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
260 Johkoh T, Lee KS, Nishino M, Travis WD, Ryu JH, Lee HY, Ryerson CJ, Franquet T, Bankier AA, Brown KK, Goo JM, Kauczor HU, Lynch DA, Nicholson AG, Richeldi L, Schaefer-Prokop CM, Verschakelen J, Raoof S, Rubin GD, Powell C, Inoue Y, Hatabu H. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. Chest 2021;159:1107-25. [PMID: 33450293 DOI: 10.1016/j.chest.2020.11.027] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
261 Thuillier P, Joly C, Alavi Z, Crouzeix G, Descourt R, Quere G, Kerlan V, Roudaut N. Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study. Cancer Immunol Immunother 2021;70:2023-33. [PMID: 33423089 DOI: 10.1007/s00262-020-02802-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
262 Zhang M, Rodrigues AJ, Pollom EL, Gibbs IC, Soltys SG, Hancock SL, Neal JW, Padda SK, Ramchandran KJ, Wakelee HA, Chang SD, Lim M, Hayden Gephart M, Li G. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases. J Neurooncol 2021;152:125-34. [PMID: 33415659 DOI: 10.1007/s11060-020-03686-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
263 Abdel-Wahab N, Diab A, Yu RK, Futreal A, Criswell LA, Tayar JH, Dadu R, Shannon V, Shete SS, Suarez-Almazor ME. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:1939-49. [PMID: 33409738 DOI: 10.1007/s00262-020-02797-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
264 Yamagata A, Yokoyama T, Fukuda Y, Ishida T. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 2021;87:251-8. [PMID: 33394102 DOI: 10.1007/s00280-020-04205-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
265 Zamora C, Riudavets M, Anguera G, Alserawan L, Sullivan I, Barba A, Serra J, Ortiz MA, Gallardo P, Perea L, Gavira J, Barnadas A, Majem M, Vidal S. Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents. Cancer Immunol Immunother 2021;70:1691-704. [PMID: 33388994 DOI: 10.1007/s00262-020-02793-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
266 Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, Fernandes R. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors – A systematic review and meta-analysis. Cancer Treatment Reviews 2021;92:102134. [DOI: 10.1016/j.ctrv.2020.102134] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 38.0] [Reference Citation Analysis]
267 D'Andréa G, Lassalle S, Guevara N, Mograbi B, Hofman P. From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer. Theranostics 2021;11:1310-25. [PMID: 33391536 DOI: 10.7150/thno.50333] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
268 Cappelli LC, Bingham CO. Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Arthritis. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy 2021. [DOI: 10.1007/978-3-030-56824-5_4] [Reference Citation Analysis]
269 Rengarajan M, Gainor JF. Endocrine immune-related adverse events: a double-edged sword? Transl Lung Cancer Res 2021;10:13-7. [PMID: 33569289 DOI: 10.21037/tlcr-2020-16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
270 Satoh T, Kato K, Ura T, Hamamoto Y, Kojima T, Tsushima T, Hironaka S, Hara H, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Matsumura Y, Kitagawa Y. Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07). Esophagus 2021;18:835-43. [PMID: 33993388 DOI: 10.1007/s10388-021-00850-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
271 Zhao L, Li L, Chen T, Fang C. Effective Treatment of NSCLC with Surgery After Nivolumab Combined with Chemotherapy: A Case Report and Brief Review of the Literature. Onco Targets Ther 2020;13:13307-13. [PMID: 33408481 DOI: 10.2147/OTT.S266155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
272 Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2020;6:519-27. [PMID: 31895407 DOI: 10.1001/jamaoncol.2019.5570] [Cited by in Crossref: 173] [Cited by in F6Publishing: 183] [Article Influence: 57.7] [Reference Citation Analysis]
273 Allegra A, Di Salvo E, Casciaro M, Musolino C, Pioggia G, Gangemi S. The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients. Biomedicines 2020;9:2. [PMID: 33375183 DOI: 10.3390/biomedicines9010002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
274 Khatami M. Deceptology in cancer and vaccine sciences: Seeds of immune destruction-mini electric shocks in mitochondria: Neuroplasticity-electrobiology of response profiles and increased induced diseases in four generations - A hypothesis. Clin Transl Med 2020;10:e215. [PMID: 33377661 DOI: 10.1002/ctm2.215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
275 Elmore LW, Greer SF, Daniels EC, Saxe CC, Melner MH, Krawiec GM, Cance WG, Phelps WC. Blueprint for cancer research: Critical gaps and opportunities. CA Cancer J Clin 2021;71:107-39. [PMID: 33326126 DOI: 10.3322/caac.21652] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
276 Conde-estévez D, Monge-escartín I, Ríos-hoyo A, Monzonis X, Echeverría-esnal D, Moliner L, Duran-jordà X, Taus Á, Arriola E. Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage. Journal of Chemotherapy 2021;33:32-9. [DOI: 10.1080/1120009x.2020.1849488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
277 Vitale MG, Pipitone S, Venturelli M, Baldessari C, Porta C, Iannuzzi F, Basso U, Scagliarini S, Zucali PA, Galli L, Rossetti S, Caserta C, Bracarda S, Iacovelli R, Masini C, Cortellini A, Di Girolamo S, Buti S, Fornarini G, Carrozza F, Santoni M, Caputo F, Giaquinta S, Balduzzi S, D’amico R, Vitale G, Mighali P, Sabbatini R. Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Clinical Genitourinary Cancer 2020;18:477-88. [DOI: 10.1016/j.clgc.2020.05.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
278 Akturk HK, Michels AW. Adverse events associated with immune checkpoint inhibitors: a new era in autoimmune diabetes. Curr Opin Endocrinol Diabetes Obes 2020;27:187-93. [PMID: 32618630 DOI: 10.1097/MED.0000000000000546] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
279 Saito Y, Uchiyama K, Sakamoto T, Yamazaki K, Kubota K, Takekuma Y, Komatsu Y, Sugawara M. Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors. Biological & Pharmaceutical Bulletin 2020;43:1969-1974. [DOI: 10.1248/bpb.b20-00553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
280 Jacob S, Rahbari K, Tegtmeyer K, Zhao J, Tran S, Helenowski I, Zhang H, Walunas T, Varga J, Dematte J, Villaflor V. Lung Cancer Survival in Patients With Autoimmune Disease. JAMA Netw Open 2020;3:e2029917. [PMID: 33315114 DOI: 10.1001/jamanetworkopen.2020.29917] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
281 Dall'Olio FG, Rizzo A, Mollica V, Massucci M, Maggio I, Massari F. Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. Immunotherapy 2021;13:257-70. [PMID: 33225800 DOI: 10.2217/imt-2020-0179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
282 Alekseev BY, Shevchuk IM. Combination of nivolumab and ipilimumab in the treatment of disseminated renal cell carcinoma. Realities and prospects. Onkourologiâ 2020;16:38-52. [DOI: 10.17650/1726-9776-2020-16-3-38-52] [Reference Citation Analysis]
283 Matsuki T, Okamoto I, Fushimi C, Takahashi H, Okada T, Kondo T, Sato H, Ito T, Tokashiki K, Tsukahara K, Hanyu K, Masubuchi T, Tada Y, Miura K, Omura G, Sawabe M, Kawakita D, Yamashita T. Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients. Cancers (Basel) 2020;12:E3427. [PMID: 33218183 DOI: 10.3390/cancers12113427] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
284 Isono T, Kagiyama N, Takano K, Hosoda C, Nishida T, Kawate E, Kobayashi Y, Ishiguro T, Takaku Y, Kurashima K, Yanagisawa T, Takayanagi N. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. Thorac Cancer 2021;12:153-64. [PMID: 33201587 DOI: 10.1111/1759-7714.13736] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
285 Unterrainer M, Ruzicka M, Fabritius MP, Mittlmeier LM, Winkelmann M, Rübenthaler J, Brendel M, Subklewe M, von Bergwelt-Baildon M, Ricke J, Kunz WG, Cyran CC. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp 2020;4:63. [PMID: 33200246 DOI: 10.1186/s41747-020-00190-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
286 Kamta J, Magruder B, Hymel L. Implementation of a pharmacy consult service for evaluation of immune checkpoint inhibitor related adverse events at a large community hospital. J Oncol Pharm Pract 2020;:1078155220970266. [PMID: 33176559 DOI: 10.1177/1078155220970266] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
287 Bade BC, Possick JD. Pulmonary Complications of Immunotherapy. Clin Chest Med 2020;41:295-305. [PMID: 32402364 DOI: 10.1016/j.ccm.2020.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
288 Yatsuda Y, Hirose S, Ito Y, Onoda T, Sugiyama Y, Nagafuchi M, Suzuki H, Niisato Y, Tange Y, Ikeda T, Yamada T, Yamamoto Y, Ohyama Osawa M, Sakamoto N, Moriwaki T, Mizokami Y. A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient. Intern Med 2021;60:1011-7. [PMID: 33162479 DOI: 10.2169/internalmedicine.5893-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
289 Castello A, Lopci E. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. Curr Radiopharm 2020;13:24-31. [PMID: 31749440 DOI: 10.2174/1874471012666191015100106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
290 Sheikhbahaei S, Verde F, Hales RK, Rowe SP, Solnes LB. Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of 18F-FDG PET/CT. Clinical Lung Cancer 2020;21:485-97. [DOI: 10.1016/j.cllc.2020.06.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
291 Riudavets M, Caramella C, Pradere P, Naltet C, Le Pechoux C, Adam J, Mabille L, Rouleau E, Besse B, Planchard D. Complete, Unpredictable, Multi-site Response Including Brain and Liver Metastases in a Patient With RET-rearranged Non-small-cell Lung Cancer Treated With Single-agent Immunotherapy: A Case Report. Clin Lung Cancer 2021;22:e215-9. [PMID: 33187915 DOI: 10.1016/j.cllc.2020.10.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
292 Huang L, Li L, Zhou Y, Yang Z, Wang M, Gao Y, Yang Y, Yang F, Liu B, Hong X, Chen G. Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer. J Cancer 2020;11:7137-45. [PMID: 33193876 DOI: 10.7150/jca.49213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
293 Durrechou Q, Domblides C, Sionneau B, Lefort F, Quivy A, Ravaud A, Gross-Goupil M, Daste A. Management of Immune Checkpoint Inhibitor Toxicities. Cancer Manag Res 2020;12:9139-58. [PMID: 33061607 DOI: 10.2147/CMAR.S218756] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
294 Joseph A, Simonaggio A, Stoclin A, Vieillard-Baron A, Geri G, Oudard S, Michot JM, Lambotte O, Azoulay E, Lemiale V. Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. Ann Intensive Care 2020;10:143. [PMID: 33064239 DOI: 10.1186/s13613-020-00761-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
295 Minemura H, Moriya H, Imai H, Sugiyama T, Yamada Y, Higuchi M, Kaira K, Ozaki Y, Kanazawa K, Yokouchi H, Kasai T, Kaburagi T, Suzuki H, Minato K, Shibata Y. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab. Thorac Cancer 2020;11:3521-7. [PMID: 33044045 DOI: 10.1111/1759-7714.13695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
296 Schweizer C, Schubert P, Rutzner S, Eckstein M, Haderlein M, Lettmaier S, Semrau S, Gostian AO, Frey B, Gaipl US, Zhou JG, Fietkau R, Hecht M. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. Eur J Cancer 2020;140:55-62. [PMID: 33045663 DOI: 10.1016/j.ejca.2020.09.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
297 Yuen CA, Rezania K, Park DM, Reder AT. Asymptomatic brainstem lesions and pachymeningeal enhancement after anti-PD-1 therapy. Immunotherapy 2021;13:11-7. [PMID: 33023359 DOI: 10.2217/imt-2020-0186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
298 Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, Yang Y, Diao L, Lin SH, Mills GB, Zhuang G, Xue X, Han L. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun 2020;11:4946. [PMID: 33009409 DOI: 10.1038/s41467-020-18742-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 18.7] [Reference Citation Analysis]
299 Silvestris N, Argentiero A, Beretta GD, Di Bartolo P, Montagnani M, Danesi R, Ferrari P, D'Oronzo S, Gori S, Russo A, Acquati S, Gallo M. Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 2020;154:103066. [PMID: 32853883 DOI: 10.1016/j.critrevonc.2020.103066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
300 Shen Y, Chen Y, Wang D, Zhu Z. Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade. Medicine (Baltimore) 2020;99:e22153. [PMID: 32925773 DOI: 10.1097/MD.0000000000022153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
301 Simoes CC, Thung SN, Fiel MI, Sung MW, Schwartz ME, Ward SC. Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy. Mod Pathol 2021;34:823-33. [PMID: 32989224 DOI: 10.1038/s41379-020-00679-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
302 Economopoulou P, Kotsantis I, Papaxoinis G, Gavrielatou N, Anastasiou M, Pantazopoulos A, Kavourakis G, Gkolfinopoulos S, Panayiotides I, Delides A, Psyrri A. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncol 2020;111:105013. [PMID: 32977184 DOI: 10.1016/j.oraloncology.2020.105013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
303 Juarez RD, Taliaferro A, Behr SC. Functional Imaging of Immunotherapy: Response Criteria, Imaging Characteristics, and Novel Immunoimaging of Advanced Malignancies. Curr Radiol Rep 2020;8. [DOI: 10.1007/s40134-020-00369-9] [Reference Citation Analysis]
304 Fournel L, Boudou-Rouquette P, Prieto M, Hervochon R, Guinet C, Arrondeau J, Alexandre J, Damotte D, Wislez M, Batteux F, Icard P, Goldwasser F, Alifano M. Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. Cancer Chemother Pharmacol 2020;86:497-505. [PMID: 32936316 DOI: 10.1007/s00280-020-04142-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
305 Zhu S, Fu Y, Zhu B, Zhang B, Wang J. Pneumonitis Induced by Immune Checkpoint Inhibitors: From Clinical Data to Translational Investigation. Front Oncol 2020;10:1785. [PMID: 33042827 DOI: 10.3389/fonc.2020.01785] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
306 Park H, Hatabu H, Ricciuti B, Aijazi SJ, Awad MM, Nishino M. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. Eur J Radiol 2020;132:109275. [PMID: 32949913 DOI: 10.1016/j.ejrad.2020.109275] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
307 Riudavets M, Mosquera J, Garcia-Campelo R, Serra J, Anguera G, Gallardo P, Sullivan I, Barba A, Del Carpio L, Barnadas A, Gich I, Majem M. Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents. Front Oncol 2020;10:1677. [PMID: 33014837 DOI: 10.3389/fonc.2020.01677] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
308 Thompson L, Chen S. Tocilizumab and other targeted therapies for severe cutaneous immune‐related adverse events. Br J Dermatol 2020;183:613-613. [DOI: 10.1111/bjd.19322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
309 Jin J, Stabile LP. When fat is favorable: the unexpected relationship between obesity and response to immunotherapy. Immunotherapy 2020;12:1035-9. [PMID: 32878516 DOI: 10.2217/imt-2020-0219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
310 Frelau A, Palard-Novello X, Jali E, Boussemart L, Dupuy A, James P, Devillers A, Le Jeune F, Edeline J, Lesimple T, Girard A. Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. Cancer Immunol Immunother 2021;70:679-87. [PMID: 32880684 DOI: 10.1007/s00262-020-02712-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
311 Fan J, Shen X, Wang Y, Zhou HL, Liu G, Li YL, Xu ZX. Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomed Pharmacother 2020;130:110621. [PMID: 34321165 DOI: 10.1016/j.biopha.2020.110621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
312 Yokohama K, Asai A, Matsui M, Okamoto N, Yasuoka H, Nishikawa T, Ohama H, Tsuchimoto Y, Inoue Y, Fukunishi S, Uchiyama K, Higuchi K. Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy. Sci Rep 2020;10:14470. [PMID: 32879383 DOI: 10.1038/s41598-020-71561-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
313 Martin C, Lupinacci L, Perazzo F, Bas C, Carranza O, Puparelli C, Kowalyszyn R, Magri I, Varela M, Richardet E, Vera K, Foglia S, Jerez I, Aman E, Martinengo G, Batagelj E, Dri A, Pilnik N, Roa GM, Mando P, Tsou F, Recondo G, Cayol F, Flores M, Sena S, Bagnes C, Waisberg FD, Minatta JN, Rizzo M. Efficacy and Safety of Nivolumab in Previously Treated Patients With Non–Small-cell Lung Cancer: Real World Experience in Argentina. Clinical Lung Cancer 2020;21:e380-7. [DOI: 10.1016/j.cllc.2020.02.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
314 Sakamoto K, Fukihara J, Morise M, Hashimoto N. Clinical burden of immune checkpoint inhibitor-induced pneumonitis. Respiratory Investigation 2020;58:305-19. [DOI: 10.1016/j.resinv.2020.05.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
315 Aoki S, Yasui M, Tajirika H, Terao H, Funahashi M, Ohta J. Pembrolizumab-Induced Severe Neuropathy in a Patient with Metastatic Urothelial Carcinoma after Achieving Complete Response: Guillain-Barré Syndrome-Like Onset. Case Rep Oncol 2020;13:1490-4. [PMID: 33564288 DOI: 10.1159/000511567] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
316 Flavell RR, Evans MJ, Villanueva-Meyer JE, Yom SS. Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. Int J Radiat Oncol Biol Phys 2020;108:242-57. [PMID: 32585333 DOI: 10.1016/j.ijrobp.2020.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
317 Tambo Y, Sone T, Shibata K, Nishi K, Shirasaki H, Yoneda T, Araya T, Kase K, Nishikawa S, Kimura H, Kasahara K. Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non–Small-Cell Lung Cancer and High PD-L1 Tumor Expression. Clinical Lung Cancer 2020;21:e366-79. [DOI: 10.1016/j.cllc.2020.02.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
318 Gershner KA. Immunotherapy-induced Pneumonitis: A Review of Diagnostic Workup and Treatment Guidelines. Clinical Pulmonary Medicine 2020;27:141-147. [DOI: 10.1097/cpm.0000000000000373] [Reference Citation Analysis]
319 Albrethsen M, Creeden J, Morand S, DeBiase J, Berry B, Stanbery L, Edelman G, Nemunaitis J. Relationship of hypothyroidism and immune response to pegylated IL-10/nivolumab. Immunotherapy 2020;12:1041-6. [PMID: 32808556 DOI: 10.2217/imt-2020-0016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
320 Dudzińska M, Szczyrek M, Wojas-Krawczyk K, Świrska J, Chmielewska I, Zwolak A. Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review. Cancers (Basel) 2020;12:E2314. [PMID: 32824462 DOI: 10.3390/cancers12082314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
321 Tomisaki I. Editorial Comment to Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer. IJU Case Rep 2020;3:20. [PMID: 32743460 DOI: 10.1002/iju5.12132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
322 Garrett NFMDS, da Costa ACC, Damiani G, Vasques CI. Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities. Critical Reviews in Oncology/Hematology 2020;152:102983. [DOI: 10.1016/j.critrevonc.2020.102983] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
323 Chen Y, Gao M, Huang Z, Yu J, Meng X. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. J Hematol Oncol 2020;13:105. [PMID: 32723363 DOI: 10.1186/s13045-020-00940-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
324 Li H, Zhou X, Zhang D, Wang G, Cheng X, Xu C, Yao B, Pang L, Chen J. Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature. Front Med (Lausanne) 2020;7:366. [PMID: 32850889 DOI: 10.3389/fmed.2020.00366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
325 Kijima T, Fukushima H, Kusuhara S, Tanaka H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Sakai Y, Saito K, Matsubara N, Yuasa T, Masuda H, Yonese J, Kageyama Y, Fujii Y. Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review. Clin Genitourin Cancer 2021;19:208-216.e1. [PMID: 32800718 DOI: 10.1016/j.clgc.2020.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
326 Ricciuti B, Naqash AR, Naidoo J, Sehgal K, Miller A, Kehl K, Venkatraman D, Sands J, Lamberti G, Recondo G, Zhang J, Macherla S, Baig S, Walker P, Rangachari D, Gainor JF, Costa DB, Rizvi N, Sholl LM, Nishino M, Henick B, Farago AF, Awad MM. Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clin Res Rep 2020;1:100074. [PMID: 34589955 DOI: 10.1016/j.jtocrr.2020.100074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
327 Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, Donskov F, Plimack ER, Barthélémy P, Hammers HJ, George S, Grünwald V, Porta C, Neiman V, Ravaud A, Choueiri TK, Rini BI, Salman P, Kollmannsberger CK, Tykodi SS, Grimm MO, Gurney H, Leibowitz-Amit R, Geertsen PF, Amin A, Tomita Y, McHenry MB, Saggi SS, Tannir NM. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer 2020;8:e000891. [PMID: 32661118 DOI: 10.1136/jitc-2020-000891] [Cited by in Crossref: 103] [Cited by in F6Publishing: 108] [Article Influence: 34.3] [Reference Citation Analysis]
328 Noguchi S, Suminaga K, Kaki T, Kawachi H, Fukao A, Terashita S, Horikawa S, Ikeue T, Sugita T. Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer. Lung Cancer (Auckl) 2020;11:53-7. [PMID: 32765147 DOI: 10.2147/LCTT.S254146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
329 Sato K, Hayashi M, Abe K, Fujita M, Takahashi A, Ohira H. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report. Clin J Gastroenterol 2020;13:1310-4. [PMID: 32643124 DOI: 10.1007/s12328-020-01178-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
330 Bouhlel L, Doyen J, Chamorey E, Poudenx M, Ilie M, Gal J, Guigay J, Benzaquen J, Marquette CH, Berthet JP, Mouroux J, Schiappa R, Padovani B, Hofman P, Otto J. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bull Cancer 2020;107:946-58. [PMID: 32646604 DOI: 10.1016/j.bulcan.2020.04.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
331 Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C, Clymer J, Chi S, Yeo KK. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol 2020;149:113-22. [PMID: 32627129 DOI: 10.1007/s11060-020-03578-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
332 Kurnit KC, Reid P, Moroney JW, Fleming GF. Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. Gynecol Oncol 2020;158:531-7. [PMID: 32641238 DOI: 10.1016/j.ygyno.2020.06.499] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
333 Gong Z, Wang Y. Immune Checkpoint Inhibitor-Mediated Diarrhea and Colitis: A Clinical Review. JCO Oncol Pract 2020;16:453-61. [PMID: 32584703 DOI: 10.1200/OP.20.00002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
334 Assi HA, Asch AS, Machiorlatti M, Vesely SK, Ibrahimi S. Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy. Future Sci OA 2020;6:FSO581. [PMID: 32802390 DOI: 10.2144/fsoa-2020-0021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
335 Ye W, Olsson-brown A, Watson RA, Cheung VTF, Morgan RD, Nassiri I, Cooper R, Taylor C, Brain O, Matin RN, Coupe N, Middleton MR, Coles M, Sacco J, Payne MJ, Fairfax BP. Checkpoint-blocker induced autoimmunity is associated with pretreatment T cell expression profiles and favourable outcome in melanoma.. [DOI: 10.1101/2020.06.23.20138594] [Reference Citation Analysis]
336 Yen CJ, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). Head Neck 2020;42:2852-62. [PMID: 32583557 DOI: 10.1002/hed.26331] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
337 Brigida M, Perricelli A, Sposato F, Spadafora MG, Pomillo A, Sisto M. Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1. Rev Recent Clin Trials 2020;15:339-46. [PMID: 32568023 DOI: 10.2174/1574887115666200622161418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
338 Higashi T, Miyamoto H, Yoshida R, Furuta Y, Nagaoka K, Naoe H, Naito H, Nakayama H, Tanaka M. Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer. Intern Med 2020;59:2499-504. [PMID: 32581160 DOI: 10.2169/internalmedicine.4701-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
339 Cortellini A, Friedlaender A, Banna GL, Porzio G, Bersanelli M, Cappuzzo F, Aerts JGJV, Giusti R, Bria E, Cortinovis D, Grossi F, Migliorino MR, Galetta D, Passiglia F, Berardi R, Mazzoni F, Di Noia V, Signorelli D, Tuzi A, Gelibter A, Marchetti P, Macerelli M, Rastelli F, Chiari R, Rocco D, Inno A, Di Marino P, Mansueto G, Zoratto F, Santoni M, Tudini M, Ghidini M, Filetti M, Catino A, Pizzutilo P, Sala L, Occhipinti MA, Citarella F, Russano M, Torniai M, Cantini L, Follador A, Sforza V, Nigro O, Ferrara MG, D'Argento E, Leonetti A, Pettoruti L, Antonuzzo L, Scodes S, Landi L, Guaitoli G, Baldessari C, Bertolini F, Della Gravara L, Dal Bello MG, Belderbos RA, De Filippis M, Cecchi C, Ricciardi S, Donisi C, De Toma A, Proto C, Addeo A, Cantale O, Ricciuti B, Genova C, Morabito A, Santini D, Ficorella C, Cannita K. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes. Clin Lung Cancer 2020;21:498-508.e2. [PMID: 32680806 DOI: 10.1016/j.cllc.2020.06.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
340 Shimozaki K, Sukawa Y, Beppu N, Kurihara I, Suzuki S, Mizuno R, Funakoshi T, Ikemura S, Tsugaru K, Togasaki K, Kawasaki K, Hirata K, Hayashi H, Hamamoto Y, Takaishi H, Kanai T. Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors. Cancer Manag Res 2020;12:4585-93. [PMID: 32606951 DOI: 10.2147/CMAR.S247554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
341 Tanabe K, Kanzaki H, Wada T, Nakashima Y, Sugiyama H, Okada H, Wada J. Nivolumab-induced IgA nephropathy in a patient with advanced gastric cancer: A case report. Medicine (Baltimore) 2020;99:e20464. [PMID: 32481351 DOI: 10.1097/MD.0000000000020464] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
342 Namikawa T, Yokota K, Tanioka N, Fukudome I, Iwabu J, Munekage M, Uemura S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer. Surg Today 2020;50:1486-95. [DOI: 10.1007/s00595-020-02048-w] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
343 Ruggiero R, Fraenza F, Scavone C, di Mauro G, Piscitelli R, Mascolo A, Ferrajolo C, Rafaniello C, Sportiello L, Rossi F, Capuano A. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Front Pharmacol 2020;11:830. [PMID: 32581796 DOI: 10.3389/fphar.2020.00830] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
344 Zhang L, Zhao H. Focus on immune-related adverse events (irAEs) in immunotherapy of hepatobiliary malignancies. Hepatobiliary Surg Nutr 2020;9:348-9. [PMID: 32509826 DOI: 10.21037/hbsn.2019.10.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
345 Zhao JJ, Wen XZ, Ding Y, Li DD, Zhu BY, Li JJ, Weng DS, Zhang X, Zhang XS. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma. Aging (Albany NY) 2020;12:10663-75. [PMID: 32516130 DOI: 10.18632/aging.103285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
346 Moey MYY, Gougis P, Goldschmidt V, Johnson DB, Lebrun-Vignes B, Moslehi J, Cadranel J, Salem JE. Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis. Eur Respir J 2020;55:2000038. [PMID: 32079644 DOI: 10.1183/13993003.00038-2020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
347 Okamoto I, Sato H, Tsukahara K. DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Auris Nasus Larynx 2020:S0385-8146(20)30090-0. [PMID: 32507527 DOI: 10.1016/j.anl.2020.02.018] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
348 Ksienski D, Wai ES, Croteau NS, Freeman AT, Chan A, Fiorino L, Poonja Z, Fenton D, Patterson T, Irons S, Lesperance M. Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab. Journal of Geriatric Oncology 2020;11:807-13. [DOI: 10.1016/j.jgo.2020.01.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
349 Singh V, Chu Y, Gupta V, Zhao CW. A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma. Cureus 2020;12:e8395. [PMID: 32637277 DOI: 10.7759/cureus.8395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
350 Chen M, Li Q, Xu Y, Zhao J, Zhang L, Wei L, Zhong W, Wang M. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. Thorac Cancer 2020;11:1955-62. [PMID: 32468726 DOI: 10.1111/1759-7714.13488] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
351 Prigent K, Aide N. 18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects: A Checklist for the PET Reader. PET Clin 2020;15:1-10. [PMID: 31735296 DOI: 10.1016/j.cpet.2019.08.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
352 Frega S, Dal Maso A, Pasello G, Cuppari L, Bonanno L, Conte P, Evangelista L. Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers (Basel) 2020;12:E1303. [PMID: 32455666 DOI: 10.3390/cancers12051303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
353 Noda T, Komune N, Yasumatsu R, Tsuchihashi NA, Tamae A, Matsumoto N, Sato K, Uchi R, Koike K, Wakasaki T, Tanaka R, Nakagawa T. Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma. Auris Nasus Larynx 2020;47:864-9. [PMID: 32446629 DOI: 10.1016/j.anl.2020.03.011] [Reference Citation Analysis]
354 Falcao CK, Cabral MCS, Mota JM, Arbache ST, Costa-Riquetto AD, Muniz DQB, Cury-Martins J, Almeida MQ, Kaczemorska PC, Nery M, Teles MG. Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell Carcinoma. J Clin Endocrinol Metab 2019;104:3245-8. [PMID: 30779841 DOI: 10.1210/jc.2018-02221] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
355 Okamoto I, Sato H, Tsukahara K. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab. Auris Nasus Larynx 2020;47:676-86. [PMID: 32439271 DOI: 10.1016/j.anl.2020.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
356 Vitale G, Lamberti G, Comito F, Di Nunno V, Massari F, Morelli MC, Ardizzoni A, Gelsomino F. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. Expert Opin Biol Ther 2020;20:1047-59. [PMID: 32425081 DOI: 10.1080/14712598.2020.1762562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
357 Reuss JE, Suresh K, Naidoo J. Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. Curr Oncol Rep 2020;22:56. [PMID: 32415399 DOI: 10.1007/s11912-020-00920-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
358 Lim SM, Kim SW, Cho BC, Kang JH, Ahn MJ, Kim DW, Kim YC, Lee JS, Lee JS, Lee SY, Park KU, An HJ, Cho EK, Jang TW, Kim BS, Kim JH, Lee SS, Na II, Yoo SS, Lee KH. Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea. Cancer Res Treat 2020;52:1112-9. [PMID: 32599984 DOI: 10.4143/crt.2020.245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
359 Fuentes-Antrás J, Peinado P, Guevara-Hoyer K, Del Arco CD, Sánchez-Ramón S, Aguado C. Fatal autoimmune storm after a single cycle of anti-PD-1 therapy: A case of lethal toxicity but pathological complete response in metastatic lung adenocarcinoma. Hematol Oncol Stem Cell Ther 2020:S1658-3876(20)30098-4. [PMID: 32442551 DOI: 10.1016/j.hemonc.2020.04.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
360 Shibata Y, Murakami S. Safety evaluation of durvalumab for the treatment of non-small-cell lung cancer. Expert Opin Drug Saf 2020;19:653-9. [PMID: 32357806 DOI: 10.1080/14740338.2020.1764936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
361 Friedlaender A, Kim C, Addeo A. Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic. Front Oncol 2020;10:862. [PMID: 32574277 DOI: 10.3389/fonc.2020.00862] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
362 Cui P, Huang D, Wu Z, Tao H, Zhang S, Ma J, Liu Z, Wang J, Huang Z, Chen S, Zheng X, Hu Y. Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer. Ther Adv Med Oncol 2020;12:1758835920922033. [PMID: 32426052 DOI: 10.1177/1758835920922033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
363 Muir CA, Menzies AM, Clifton-Bligh R, Tsang VHM. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid 2020;30:1458-69. [PMID: 32264785 DOI: 10.1089/thy.2020.0032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
364 Coureau M, Meert AP, Berghmans T, Grigoriu B. Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders. Front Med (Lausanne). 2020;7:137. [PMID: 32457912 DOI: 10.3389/fmed.2020.00137] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
365 Music M, Iafolla M, Soosaipillai A, Batruch I, Prassas I, Pintilie M, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Siu LL, Diamandis EP. Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. F1000Res 2020;9:337. [PMID: 33299547 DOI: 10.12688/f1000research.22715.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
366 Okeya K, Kawagishi Y, Yamoto M, Shimizu M, Imizuda T, Tsuji H. Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment. Respirol Case Rep 2020;8:e00564. [PMID: 32337046 DOI: 10.1002/rcr2.564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
367 Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, Duruisseaux M, Kiakouama-Maleka L, Freyer G, Boespflug A, Péron J. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. Eur J Cancer 2020;132:61-70. [PMID: 32334337 DOI: 10.1016/j.ejca.2020.03.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
368 Haratani K, Hayashi H, Nakagawa K. Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary? BMC Med 2020;18:111. [PMID: 32312270 DOI: 10.1186/s12916-020-01583-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
369 Linsley PS, Long SA. Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D. Curr Opin Endocrinol Diabetes Obes 2019;26:213-8. [PMID: 31157632 DOI: 10.1097/MED.0000000000000488] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
370 Botticelli A, Mezi S, Pomati G, Sciattella P, Cerbelli B, Roberto M, Mammone G, Cirillo A, Cassano A, Di Dio C, Cortellini A, Pizzuti L, Ronzino G, Salati M, Vici P, Polimeni A, Merlano MC, Nuti M, Marchetti P. The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. Vaccines (Basel) 2020;8:E191. [PMID: 32326034 DOI: 10.3390/vaccines8020191] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
371 Schiwitza A, Schildhaus HU, Zwerger B, Rüschoff J, Reinhardt C, Leha A, Andreas S, Rittmeyer A. Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Immunotherapy 2019;11:769-82. [PMID: 31120392 DOI: 10.2217/imt-2019-0039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
372 Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 2020;18:87. [PMID: 32306958 DOI: 10.1186/s12916-020-01549-2] [Cited by in Crossref: 96] [Cited by in F6Publishing: 103] [Article Influence: 32.0] [Reference Citation Analysis]
373 Suzuki K, Yanagihara T, Matsumoto K, Kusaba H, Yamauchi T, Ikematsu Y, Tanaka K, Otsubo K, Inoue H, Yoneshima Y, Iwama E, Arimura-Omori M, Harada E, Hamada N, Okamoto I, Nakanishi Y. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. Int Immunol 2020;32:547-57. [PMID: 32253426 DOI: 10.1093/intimm/dxaa022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
374 Ueki Y, Takahashi T, Ota H, Shodo R, Yamazaki K, Horii A. Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score. Eur Arch Otorhinolaryngol 2020;277:2341-7. [DOI: 10.1007/s00405-020-05945-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
375 Scotté F, Ratta R, Beuzeboc P. Side effects of immunotherapy: a constant challenge for oncologists. Curr Opin Oncol 2019;31:280-5. [PMID: 30925538 DOI: 10.1097/CCO.0000000000000541] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
376 Ida H, Goto Y, Sato J, Kanda S, Shinno Y, Morita R, Murakami S, Matsumoto Y, Yoshida T, Horinouchi H, Fujiwara Y, Yamamoto N, Fukuda T, Ohashi K, Ohe Y. Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer. Med Oncol 2020;37:30. [PMID: 32180046 DOI: 10.1007/s12032-020-01357-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
377 Okada T, Hamamoto S, Etani T, Naiki T, Sue Y, Banno R, Yamada K, Sakakura T, Yasui T. Complete response of renal cell carcinoma with an inferior vena cava tumor thrombus and lung metastases after treatment with nivolumab plus ipilimumab. Int Cancer Conf J 2020;9:88-91. [PMID: 32257760 DOI: 10.1007/s13691-020-00403-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
378 Watanabe S, Ota T, Hayashi M, Ishikawa H, Otsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Miyabayashi T, Miura S, Tanaka H, Abe T, Okajima M, Terada M, Ishida T, Iwashima A, Sato K, Yoshizawa H, Kikuchi T. Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy. Cancer Med 2020;9:3070-7. [PMID: 32150668 DOI: 10.1002/cam4.2974] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
379 Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, Sugawara S, Burkart J, Park W, Chiari R, Sugisaka J, Otterson GA, de Lima Lopes G, Walker PR. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother 2020;69:1177-87. [PMID: 32140762 DOI: 10.1007/s00262-020-02536-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
380 Yang H, Yao Z, Zhou X, Zhang W, Zhang X, Zhang F. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. Clin Immunol 2020;213:108377. [PMID: 32135278 DOI: 10.1016/j.clim.2020.108377] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
381 Cortellini A, Bersanelli M, Santini D, Buti S, Tiseo M, Cannita K, Perrone F, Giusti R, De Tursi M, Zoratto F, Marconcini R, Russano M, Zeppola T, Anesi C, Filetti M, Marchetti P, Botticelli A, Gelibter A, De Galitiis F, Vitale MG, Rastelli F, Tudini M, Silva RR, Atzori F, Chiari R, Ricciuti B, De Giglio A, Migliorino MR, Mallardo D, Vanella V, Mosillo C, Bracarda S, Rinaldi S, Berardi R, Natoli C, Ficorella C, Porzio G, Ascierto PA. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer 2020;128:17-26. [DOI: 10.1016/j.ejca.2019.12.031] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 16.0] [Reference Citation Analysis]
382 Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol 2020;200:131-40. [PMID: 32027018 DOI: 10.1111/cei.13424] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 18.7] [Reference Citation Analysis]
383 Gandy N, Arshad MA, Wallitt KL, Dubash S, Khan S, Barwick TD. Immunotherapy-related adverse effects on 18F-FDG PET/CT imaging. Br J Radiol 2020;93:20190832. [PMID: 32105505 DOI: 10.1259/bjr.20190832] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
384 Sugano T, Seike M, Saito Y, Kashiwada T, Terasaki Y, Takano N, Hisakane K, Takahashi S, Tanaka T, Takeuchi S, Miyanaga A, Minegishi Y, Noro R, Kubota K, Gemma A. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. Thorac Cancer 2020;11:1052-60. [PMID: 32096610 DOI: 10.1111/1759-7714.13364] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
385 Indini A, Rijavec E, Grossi F. Immune related adverse events and response to immunotherapy: Focus on corticosteroids. Lung Cancer 2020;145:225. [PMID: 32089331 DOI: 10.1016/j.lungcan.2020.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
386 Suo A, Chan Y, Beaulieu C, Kong S, Cheung WY, Monzon JG, Smylie M, Walker J, Morris D, Cheng T. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma. Oncologist 2020;25:438-46. [PMID: 32048768 DOI: 10.1634/theoncologist.2019-0674] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 10.7] [Reference Citation Analysis]
387 Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng HW, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019;5:1043-7. [PMID: 31021392 DOI: 10.1001/jamaoncol.2019.0402] [Cited by in Crossref: 164] [Cited by in F6Publishing: 174] [Article Influence: 54.7] [Reference Citation Analysis]
388 Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Hirano K, Matsumoto H, Kominami R, Tomii K, Suzuki H, Hirashima T, Uchida J, Morita M, Kanazu M, Sawa N, Makio T, Hara S, Tamiya M. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Clin Lung Cancer 2020;21:e315-28. [PMID: 32113737 DOI: 10.1016/j.cllc.2020.01.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
389 Saleh K, Khalife-Saleh N, Kourie HR. Do immune-related adverse events correlate with response to immune checkpoint inhibitors? Immunotherapy 2019;11:257-9. [PMID: 30678551 DOI: 10.2217/imt-2018-0201] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
390 Kim KH, Hur JY, Cho J, Ku BM, Koh J, Koh JY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ, Shin EC. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. Oncoimmunology 2020;9:1722023. [PMID: 32076579 DOI: 10.1080/2162402X.2020.1722023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
391 Akagi Y, Awano N, Inomata M, Kuse N, Tone M, Yoshimura H, Jo T, Takada K, Kumasaka T, Izumo T. Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma. Intern Med 2020;59:1075-80. [PMID: 32009093 DOI: 10.2169/internalmedicine.3889-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
392 Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol 2020;72:307-19. [PMID: 31954494 DOI: 10.1016/j.jhep.2019.09.025] [Cited by in Crossref: 183] [Cited by in F6Publishing: 183] [Article Influence: 61.0] [Reference Citation Analysis]
393 Wang X, Wu S, Chen Y, Shao E, Zhuang T, Lu L, Chen X. Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. Front Pharmacol 2020;11:5. [PMID: 32076409 DOI: 10.3389/fphar.2020.00005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
394 Lim SM, Hong MH, Kim HR. Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. Immune Netw 2020;20:e10. [PMID: 32158598 DOI: 10.4110/in.2020.20.e10] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 19.3] [Reference Citation Analysis]
395 Otsuka M, Sugihara S, Mori S, Hamada K, Sasaki Y, Yoshikawa S, Kiyohara Y. Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan. J Dermatol 2020;47:356-62. [PMID: 31984569 DOI: 10.1111/1346-8138.15246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
396 Sugisaka J, Toi Y, Taguri M, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Ono H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S. Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab. JMA J 2020;3:58-66. [PMID: 33324776 DOI: 10.31662/jmaj.2019-0005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
397 Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities from Disproportionality Analysis of the FDA Adverse Event Reporting System. Target Oncol. 2019;14:205-221. [PMID: 30927173 DOI: 10.1007/s11523-019-00632-w] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 17.3] [Reference Citation Analysis]
398 Cappelli LC, Dorak MT, Bettinotti MP, Bingham CO, Shah AA. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford) 2019;58:476-80. [PMID: 30508191 DOI: 10.1093/rheumatology/key358] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 16.0] [Reference Citation Analysis]
399 Kotwal A, Kottschade L, Ryder M. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. Thyroid 2020;30:177-84. [PMID: 31813343 DOI: 10.1089/thy.2019.0250] [Cited by in Crossref: 68] [Cited by in F6Publishing: 74] [Article Influence: 22.7] [Reference Citation Analysis]
400 Cortellini A, Buti S, Bersanelli M, Giusti R, Perrone F, Di Marino P, Tinari N, De Tursi M, Grassadonia A, Cannita K, Tessitore A, Zoratto F, Veltri E, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Cappellini GCA, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Gelibter A, Occhipinti MA, Martella F, Inno A, Gori S, Bracarda S, Zannori C, Mosillo C, Parisi A, Porzio G, Mallardo D, Fargnoli MC, Tiseo M, Santini D, Ascierto PA, Ficorella C. Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. Oncoimmunology 2020;9:1710389. [PMID: 32002308 DOI: 10.1080/2162402X.2019.1710389] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
401 Kostine M, Marabelle A, Schaeverbeke T, Kfoury M. [Toxicities of immune checkpoint inhibitors and their management]. Med Sci (Paris) 2019;35:949-56. [PMID: 31903899 DOI: 10.1051/medsci/2019191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
402 Park H, Nishino M. Drug Toxicity, Approach to Cancer as a Systemic Disease, and Imaging Modality-Specific Considerations. Therapy Response Imaging in Oncology 2020. [DOI: 10.1007/978-3-030-31171-1_3] [Reference Citation Analysis]
403 Sakakibara-konishi J, Sato M, Sato MT, Kasahara K, Onozawa M, Mizugaki H, Kikuchi E, Asahina H, Shinagawa N, Konno S. Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma. Respiratory Medicine Case Reports 2020;31:101170. [DOI: 10.1016/j.rmcr.2020.101170] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
404 Takenouchi A, Sato S, Kosaka T, Akiyama H, Kunisaki C, Endo I. A Case of Isolated ACTH Deficiency and Polyarthritis during Nivolumab Therapy for Gastric Cancer. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2020;81:1120-1126. [DOI: 10.3919/jjsa.81.1120] [Reference Citation Analysis]
405 Patil PD, Panchabhai TS. Pulmonary Toxicities of Immunotherapy. Handbook of Cancer Treatment-Related Symptons and Toxicities 2020. [DOI: 10.1016/b978-0-323-67241-2.00021-5] [Reference Citation Analysis]
406 Lopci E, Meignan M. Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas. PET Clinics 2020;15:23-34. [DOI: 10.1016/j.cpet.2019.08.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
407 Baseri B, Samra B, Tam E, Chiu E, Leaf A. An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. Case Rep Oncol Med 2019;2019:1816472. [PMID: 31885970 DOI: 10.1155/2019/1816472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
408 Ashinuma H, Mizuno S, Yoshida Y, Shingyoji M. A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer. Case Rep Oncol Med 2019;2019:4836404. [PMID: 31949964 DOI: 10.1155/2019/4836404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
409 Matsuo M, Yasumatsu R, Masuda M, Toh S, Wakasaki T, Hashimoto K, Taura M, Uchi R, Nakagawa T. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncol 2020;101:104525. [PMID: 31863963 DOI: 10.1016/j.oraloncology.2019.104525] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
410 Kagoshima H, Hori R, Kojima T, Okanoue Y, Fujimura S, Taguchi A, Hasebe K, Yamamoto H, Shoji K. Marked anti-tumor effects of nivolumab on recurrent/metastatic head and neck cancer: 4 case reports. Tenri Med Bull 2019;22:79-85. [DOI: 10.12936/tenrikiyo.22-012] [Reference Citation Analysis]
411 Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol 2019;5:376-83. [PMID: 30589930 DOI: 10.1001/jamaoncol.2018.5860] [Cited by in Crossref: 139] [Cited by in F6Publishing: 154] [Article Influence: 34.8] [Reference Citation Analysis]
412 Imai H, Wasamoto S, Yamaguchi O, Suzuki K, Sugiyama T, Uchino J, Minemura H, Osaki T, Ishii H, Umeda Y, Mori K, Kotake M, Kagamu H, Morozumi N, Taniguchi H, Kasai T, Minato K, Kaira K. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. J Cancer Res Clin Oncol 2020;146:457-66. [PMID: 31853661 DOI: 10.1007/s00432-019-03072-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
413 Imoto K, Kohjima M, Hioki T, Kurashige T, Kurokawa M, Tashiro S, Suzuki H, Kuwano A, Tanaka M, Okada S, Kato M, Ogawa Y. Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. Can J Gastroenterol Hepatol. 2019;2019:6391712. [PMID: 31929981 DOI: 10.1155/2019/6391712] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
414 Bersanelli M, Lattanzi E, D'Abbiero N, Buti S, Leonetti A, Canè MG, Trapani S, Gravina G, Porzio G, Cannita K, Marino PD, Grassadonia A, Tinari N, Tursi M, Giaiacopi E, Michiara M, Bordi P, Perrone F, Caravatta L, Trignani M, Genovesi D, Natoli C, Ficorella C, Tiseo M, Cortellini A. Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study. Biomed Rep 2020;12:59-67. [PMID: 31929875 DOI: 10.3892/br.2019.1265] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
415 Xing P, Zhang F, Wang G, Xu Y, Li C, Wang S, Guo Y, Cai S, Wang Y, Li J. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J Immunother Cancer 2019;7:341. [PMID: 31801636 DOI: 10.1186/s40425-019-0779-6] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 20.5] [Reference Citation Analysis]
416 Li Y, Wang Z, Guo T, Liu S, Feng C. Treatment-related adverse events and response rate to immune checkpoint inhibition. J Int Med Res 2020;48:300060519886454. [PMID: 31777292 DOI: 10.1177/0300060519886454] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
417 Hirsch L, Bellesoeur A, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Kirchgesner J, Gervais C, Jouinot A, Chapron J, Giraud F, Wislez M, Alexandre J, Blanchet B, Goldwasser F. The impact of body composition parameters on severe toxicity of nivolumab. Eur J Cancer 2020;124:170-7. [PMID: 31794927 DOI: 10.1016/j.ejca.2019.11.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
418 Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563-80. [PMID: 31092901 DOI: 10.1038/s41571-019-0218-0] [Cited by in Crossref: 690] [Cited by in F6Publishing: 739] [Article Influence: 172.5] [Reference Citation Analysis]
419 Cordes LM, Davarpanah NN, Reoma LB, Gasmi B, Quezado M, Khan OI, Nath A, Apolo AB. Neurotoxicities associated with checkpoint inhibitors: Two case reports and a review of the literature. Clin Case Rep 2020;8:24-32. [PMID: 31998480 DOI: 10.1002/ccr3.2534] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
420 Labadie BW, Liu P, Bao R, Crist M, Fernandes R, Ferreira L, Graupner S, Poklepovic AS, Duran I, Maleki Vareki S, Balar AV, Luke JJ. BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. J Transl Med 2019;17:386. [PMID: 31767020 DOI: 10.1186/s12967-019-02144-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
421 Azuma K. Basics of Cancer Immunotherapy. JJLC 2019;59:1119-1121. [DOI: 10.2482/haigan.59.1119] [Reference Citation Analysis]
422 Kimura H, Araya T, Yoneda T, Shirasaki H, Kurokawa K, Sakai T, Koba H, Tambo Y, Nishikawa S, Sone T, Kasahara K. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer. Cancer Commun (Lond) 2019;39:78. [PMID: 31753015 DOI: 10.1186/s40880-019-0423-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
423 Funazo TY, Nomizo T, Ozasa H, Tsuji T, Yasuda Y, Yoshida H, Sakamori Y, Nagai H, Hirai T, Kim YH. Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Sci Rep 2019;9:17085. [PMID: 31745135 DOI: 10.1038/s41598-019-53327-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
424 Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, Tanaka M, Harutani Y, Yamagata N, Okuda Y, Furuta K, Sugimoto T, Teraoka S, Hayata A, Tokudome N, Ozawa Y, Mori K, Koh Y, Yamamoto N. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer. Oncologist 2020;25:e679-83. [PMID: 32297443 DOI: 10.1634/theoncologist.2019-0299] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
425 Menon T, Afzali A. Immune-Mediated Colitis. Curr Treat Options Gastroenterol 2019;17:506-23. [PMID: 31741212 DOI: 10.1007/s11938-019-00263-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
426 Ye C, Jamal S, Hudson M, Fifi-mah A, Roberts J. Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments. Curr Treat Options in Rheum 2019;5:272-89. [DOI: 10.1007/s40674-019-00131-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
427 Kurokawa K, Hara M, Iwakami SI, Genda T, Iwakami N, Miyashita Y, Fujioka M, Sasaki S, Takahashi K. Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma. Intern Med 2019;58:3283-7. [PMID: 31735738 DOI: 10.2169/internalmedicine.2591-18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
428 Hu C, Zhang Q, Tang Q, Zhou H, Liu W, Huang J, Liu Y, Wang Q, Zhang J, Zhou M, Sheng F, Lai W, Tian J, Li G, Zhang R. CBX4 promotes the proliferation and metastasis via regulating BMI-1 in lung cancer. J Cell Mol Med 2020;24:618-31. [PMID: 31724308 DOI: 10.1111/jcmm.14771] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
429 Dupont R, Bérard E, Puisset F, Comont T, Delord JP, Guimbaud R, Meyer N, Mazieres J, Alric L. The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study. Oncoimmunology 2020;9:1682383. [PMID: 32002292 DOI: 10.1080/2162402X.2019.1682383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
430 Napolitano M, Schipilliti FM, Trudu L, Bertolini F. Immunotherapy in head and neck cancer: The great challenge of patient selection. Crit Rev Oncol Hematol 2019;144:102829. [PMID: 31739116 DOI: 10.1016/j.critrevonc.2019.102829] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
431 Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. Clinical Lung Cancer 2019;20:442-450.e4. [DOI: 10.1016/j.cllc.2019.07.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 11.8] [Reference Citation Analysis]
432 Yang J. Lack of Robust Prognostic Biomarkers for Immunotherapy in Breast Cancer-Adverse Events. JAMA Oncol 2019;5:1639-40. [PMID: 31513256 DOI: 10.1001/jamaoncol.2019.3596] [Reference Citation Analysis]
433 Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, Aoki M, Miyamoto T, Hirano H, Honma Y, Iwasa S, Okita N, Takashima A, Kato K, Boku N. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer. 2019;19:974. [PMID: 31638948 DOI: 10.1186/s12885-019-6150-y] [Cited by in Crossref: 70] [Cited by in F6Publishing: 78] [Article Influence: 17.5] [Reference Citation Analysis]
434 Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis Rheumatol 2019;71:2100-11. [PMID: 31379105 DOI: 10.1002/art.41068] [Cited by in Crossref: 121] [Cited by in F6Publishing: 137] [Article Influence: 30.3] [Reference Citation Analysis]
435 Esfahani K, Meti N, Miller WH, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019;191:E40-E46. [PMID: 30642824 DOI: 10.1503/cmaj.180870] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
436 Autio KA, Boni V, Humphrey RW, Naing A. Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. Clin Cancer Res 2020;26:984-9. [PMID: 31601568 DOI: 10.1158/1078-0432.CCR-19-1457] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 16.8] [Reference Citation Analysis]
437 Bakacs T, Moss RW, Kleef R, Szasz MA, Anderson CC. Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer. Scand J Immunol 2019;90:e12821. [PMID: 31589347 DOI: 10.1111/sji.12821] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
438 Eun Y, Kim IY, Sun JM, Lee J, Cha HS, Koh EM, Kim H, Lee J. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep 2019;9:14039. [PMID: 31575933 DOI: 10.1038/s41598-019-50574-6] [Cited by in Crossref: 68] [Cited by in F6Publishing: 73] [Article Influence: 17.0] [Reference Citation Analysis]
439 Okamoto I, Sato H, Kondo T, Koyama N, Fushimi C, Okada T, Miura K, Matsuki T, Yamashita T, Omura G, Tsukahara K. Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer - a retrospective multicentre study. Acta Otolaryngol 2019;139:918-25. [PMID: 31460818 DOI: 10.1080/00016489.2019.1648867] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 8.5] [Reference Citation Analysis]
440 Sakakida T, Ishikawa T, Chihara Y, Harita S, Uchino J, Tabuchi Y, Komori S, Asai J, Narukawa T, Arai A, Tsunezuka H, Kosuga T, Konishi H, Moriguchi M, Yasuda H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin Transl Oncol 2020;22:919-27. [PMID: 31576495 DOI: 10.1007/s12094-019-02214-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
441 Petrelli F, Grizzi G, Ghidini M, Ghidini A, Ratti M, Panni S, Cabiddu M, Ghilardi M, Borgonovo K, Parati MC, Tomasello G, Barni S, Berruti A, Brighenti M. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Journal of Immunotherapy 2020;43:1-7. [DOI: 10.1097/cji.0000000000000300] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
442 Yang X, Lin J, Wang D, Zhang L, Zhao H. Immune-Related Adverse Events (irAEs) Predict for Clinical Efficacy: Focusing on Organ-Specific irAEs and the Critical Role of Steroids. J Thorac Oncol 2019;14:e233-4. [PMID: 31558237 DOI: 10.1016/j.jtho.2019.05.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
443 Widick P, Gill RR, Mantia C, Costa DB, Rangachari D. Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis. Clin Lung Cancer 2020;21:e6-9. [PMID: 31640925 DOI: 10.1016/j.cllc.2019.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
444 Young A, Quandt Z, Bluestone JA. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunol Res 2018;6:1445-52. [PMID: 30510057 DOI: 10.1158/2326-6066.CIR-18-0487] [Cited by in Crossref: 90] [Cited by in F6Publishing: 97] [Article Influence: 22.5] [Reference Citation Analysis]
445 Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2020;25:818-830. [PMID: 31549270 DOI: 10.1007/s10147-019-01548-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 12.8] [Reference Citation Analysis]
446 Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham CO, Shah AA, Cappelli LC. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis 2020;79:332-8. [PMID: 31540935 DOI: 10.1136/annrheumdis-2019-216109] [Cited by in Crossref: 97] [Cited by in F6Publishing: 102] [Article Influence: 24.3] [Reference Citation Analysis]
447 Izumi H, Kodani M, Kurai J, Takeda K, Okazaki R, Yamane K, Teruya Y, Yamamoto A, Sueda Y, Yanai M, Tanaka N, Sakamoto T, Yamaguchi K, Makino H, Igishi T, Yamasaki A. Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature. Mol Clin Oncol 2019;11:439-46. [PMID: 31616560 DOI: 10.3892/mco.2019.1923] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
448 Hori R, Shinohara S, Kojima T, Kagoshima H, Kitamura M, Tateya I, Tamaki H, Kumabe Y, Asato R, Harada H, Kitani Y, Tsujimura T, Honda K, Ichimaru K, Omori K. Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma. Cancers (Basel) 2019;11:E1317. [PMID: 31500103 DOI: 10.3390/cancers11091317] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
449 Arias Ron D, Labandeira CM, Areses Manrique MC, Sampedro Domarco P, Abdulkader I, García-Mata J, Rolfo C, González-Rivas D, Fírvida JL. Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report. Front Oncol 2019;9:819. [PMID: 31552167 DOI: 10.3389/fonc.2019.00819] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
450 Hsiehchen D, Watters MK, Lu R, Xie Y, Gerber DE. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors. JAMA Netw Open 2019;2:e1911519. [PMID: 31532516 DOI: 10.1001/jamanetworkopen.2019.11519] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
451 Teixidor E, Bosch-Barrera J. The dark side of immunotherapy: challenges facing the new hope in cancer treatment. Ann Transl Med 2019;7:S183. [PMID: 31656762 DOI: 10.21037/atm.2019.07.69] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
452 Rassy E, Mezquita L, Remon J, Besse B. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors? Immunotherapy 2019;11:1149-60. [DOI: 10.2217/imt-2019-0071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
453 Nakajima EC, Lipson EJ, Brahmer JR. Challenge of Rechallenge: When to Resume Immunotherapy Following an Immune-Related Adverse Event. J Clin Oncol 2019;37:2714-8. [PMID: 31461381 DOI: 10.1200/JCO.19.01623] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
454 Mouri A, Kaira K, Yamaguchi O, Shiono A, Miura Y, Hashimoto K, Nishihara F, Murayama Y, Kobayashi K, Kagamu H. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. Cancer Chemother Pharmacol 2019;84:873-80. [PMID: 31444618 DOI: 10.1007/s00280-019-03926-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
455 Wei H, Jiang H, Song B. Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction. Cancer Med 2019;8:5399-413. [PMID: 31385454 DOI: 10.1002/cam4.2464] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
456 Toi Y, Sugawara S. Survivorship Bias in Analyses of Immune Checkpoint Inhibitor Trials—In Reply. JAMA Oncol 2019;5:1226. [DOI: 10.1001/jamaoncol.2019.1190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
457 Cortellini A, Buti S, Agostinelli V, Bersanelli M. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Seminars in Oncology 2019;46:362-71. [DOI: 10.1053/j.seminoncol.2019.10.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
458 Kamada S, Hanazono A, Sanpei Y, Inoue T, Suzuki S, Sugawara M, Iijima K. Alternative to steroid therapy for myasthenia gravis and myositis occurring as immune‐related adverse events. Clin Exp Neuroimmunol 2019;10:190-191. [DOI: 10.1111/cen3.12526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
459 Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies. Cancer Med 2019;8:5183-93. [PMID: 31353840 DOI: 10.1002/cam4.2411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
460 Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, Tuvy Y, Kundra R, Daian F, Ladanyi M, Kelsen DP, Ilson DH, Berger MF, Tang LH, Solit DB, Diaz LA Jr, Schultz N, Janjigian YY, Ku GY. Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clin Cancer Res 2019;25:6160-9. [PMID: 31337644 DOI: 10.1158/1078-0432.CCR-18-3603] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 12.8] [Reference Citation Analysis]
461 Komiya K, Nakamura T, Abe T, Ogusu S, Nakashima C, Takahashi K, Kimura S, Sueoka-Aragane N. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer 2019;10:1798-804. [PMID: 31328416 DOI: 10.1111/1759-7714.13149] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
462 Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Semin Cancer Biol 2020;64:93-101. [PMID: 31330185 DOI: 10.1016/j.semcancer.2019.06.012] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 16.5] [Reference Citation Analysis]
463 Pantuck M, McDermott D, Drakaki A. To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease. Cancer. 2019;125:3506-3513. [PMID: 31318445 DOI: 10.1002/cncr.32326] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
464 Jamal S, Hudson M, Fifi-mah A, Ye C. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol 2020;47:166-75. [DOI: 10.3899/jrheum.190084] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
465 Naqash AR, Appah E, Yang LV, Muzaffar M, Marie MA, Mccallen JD, Macherla S, Liles D, Walker PR. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. J Immunother Cancer 2019;7:169. [PMID: 31277704 DOI: 10.1186/s40425-019-0648-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
466 Arheden A, Skalenius J, Bjursten S, Stierner U, Ny L, Levin M, Jespersen H. Real-world data on PD-1 inhibitor therapy in metastatic melanoma. Acta Oncol 2019;58:962-6. [PMID: 31151362 DOI: 10.1080/0284186X.2019.1620966] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
467 Davar D, Kirkwood JM. PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade. JAMA Oncol 2019;5:942. [DOI: 10.1001/jamaoncol.2019.0413] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
468 Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer 2019;20:237-247.e1. [DOI: 10.1016/j.cllc.2019.02.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 19.0] [Reference Citation Analysis]
469 Bisschop C, Wind TT, Blank CU, Koornstra RH, Kapiteijn E, Van den Eertwegh AJ, De Groot JWB, Jalving M, Hospers GA. Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. Journal of Immunotherapy 2019;42:208-14. [DOI: 10.1097/cji.0000000000000271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
470 Kawai T, Sato Y, Makino K, Yamada Y, Nomiya A, Nakamura M, Yamada D, Suzuki M, Igawa Y, Kume H. Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients. European Journal of Cancer 2019;116:114-5. [DOI: 10.1016/j.ejca.2019.05.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
471 転移・再発頭頸部がんに対する分子標的薬と免疫チェックポイント阻害薬のエビデンス. Nippon Jibiinkoka Gakkai Kaiho 2019;122:848-854. [DOI: 10.3950/jibiinkoka.122.848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
472 Miura S, Isogai S, Yoshino M, Baba J, Kajiwara T, Koyama K, Takenouchi T, Tani N, Tanaka H. Management of Adverse Events Induced by Immune Checkpoint Inhibitors in Lung Cancer Treatment. JJLC 2019;59:231-237. [DOI: 10.2482/haigan.59.231] [Reference Citation Analysis]
473 Burdett N, Hsu K, Xiong L, Tapia-Rico G, Beckmann K, Karapetis C, Brown MP. Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy. Asia Pac J Clin Oncol 2020;16:e139-45. [PMID: 31215775 DOI: 10.1111/ajco.13177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
474 Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M. Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res 2019;38:268. [PMID: 31217020 DOI: 10.1186/s13046-019-1266-0] [Cited by in Crossref: 284] [Cited by in F6Publishing: 299] [Article Influence: 71.0] [Reference Citation Analysis]
475 Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol 2019;37:1927-34. [PMID: 31206316 DOI: 10.1200/JCO.19.00189] [Cited by in Crossref: 146] [Cited by in F6Publishing: 157] [Article Influence: 36.5] [Reference Citation Analysis]
476 Cao D, Xu H, Xu X, Guo T, Ge W. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Oncoimmunology. 2019;8:e1629258. [PMID: 31428527 DOI: 10.1080/2162402x.2019.1629258] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 13.5] [Reference Citation Analysis]
477 Sakakida T, Ishikawa T, Uchino J, Chihara Y, Komori S, Asai J, Narukawa T, Arai A, Kobayashi T, Tsunezuka H, Kosuga T, Konishi H, Hongo F, Inoue M, Hirano S, Ukimura O, Itoh Y, Taguchi T, Takayama K. Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. Oncol Lett 2019;18:2140-7. [PMID: 31423288 DOI: 10.3892/ol.2019.10466] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
478 Tokuyasu H, Ishikawa S, Sakai H, Ikeuchi T, Miura H. Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma. Respir Med Case Rep. 2019;28:100879. [PMID: 31249776 DOI: 10.1016/j.rmcr.2019.100879] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
479 Sibille A, Alfieri R, Malaise O, Detrembleur N, Pirotte M, Louis R, Duysinx B. Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer. Front Oncol 2019;9:478. [PMID: 31245290 DOI: 10.3389/fonc.2019.00478] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
480 Akano Y, Kuribayashi K, Funaguchi N, Koda Y, Fujimoto E, Mikami K, Minami T, Takahashi R, Yokoi T, Kijima T. Analysis of Pleiotropic Effects of Nivolumab in Pretreated Advanced or Recurrent Non-small Cell Lung Cancer Cases. In Vivo 2019;33:507-14. [PMID: 30804134 DOI: 10.21873/invivo.11503] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
481 Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, Kendra K, Ricciuti B, Chiari R, De Giglio A, Sleiman J, Funchain P, Wills B, Zhang J, Naidoo J, Philpott J, Gao J, Subudhi SK, Wang Y. Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol. 2019;37:2738-2745. [PMID: 31163011 DOI: 10.1200/jco.19.00320] [Cited by in Crossref: 79] [Cited by in F6Publishing: 93] [Article Influence: 19.8] [Reference Citation Analysis]
482 Ornstein MC, Calabrese C, Wood LS, Kirchner E, Profusek P, Allman KD, Martin A, Kontzias A, Grivas P, Garcia JA, Calabrese LH, Rini BI. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer 2019;17:177-82. [DOI: 10.1016/j.clgc.2019.01.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
483 Ando Y, Murasaki Y. 2. Cancer Immunotherapy: A Novel Approach to Cancer Treatment. Jpn J Clin Pharmacol Ther 2019;50:107-111. [DOI: 10.3999/jscpt.50.107] [Reference Citation Analysis]
484 Remon J, Esteller L, Taus Á. Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date. Cancer Manag Res 2019;11:4893-904. [PMID: 31213908 DOI: 10.2147/CMAR.S164935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
485 Sato R, Imamura K, Sakata S, Ikeda T, Horio Y, Iyama S, Akaike K, Hamada S, Jodai T, Nakashima K, Ishizuka S, Sato N, Saruwatari K, Saeki S, Tomita Y, Sakagami T. Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies. J Clin Med 2019;8:E762. [PMID: 31146442 DOI: 10.3390/jcm8060762] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
486 Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol 2018;15:477-94. [PMID: 29872177 DOI: 10.1038/s41571-018-0046-7] [Cited by in Crossref: 136] [Cited by in F6Publishing: 148] [Article Influence: 34.0] [Reference Citation Analysis]
487 Katsura H, Suga Y, Araya T, Kita T, Yoneda T, Tanaka N, Kawabata A, Ishita S, Mase H. Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status. J Cancer 2019;10:2139-44. [PMID: 31258716 DOI: 10.7150/jca.31217] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
488 Ksienski D, Wai ES, Croteau N, Freeman AT, Chan A, Fiorino L, Brooks EG, Poonja Z, Fenton D, Geller G, Irons S, Lesperance M. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice. Lung Cancer 2019;133:110-6. [PMID: 31200816 DOI: 10.1016/j.lungcan.2019.05.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
489 Quagliariello V, Passariello M, Coppola C, Rea D, Barbieri A, Scherillo M, Monti MG, Iaffaioli RV, De Laurentiis M, Ascierto PA, Botti G, De Lorenzo C, Maurea N. Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. Int J Cardiol 2019;292:171-9. [PMID: 31160077 DOI: 10.1016/j.ijcard.2019.05.028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
490 Maeda T, Yoshino K, Nagai K, Oaku S, Kato M, Hiura A, Hata H. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy. Eur J Cancer 2019;115:13-6. [PMID: 31082687 DOI: 10.1016/j.ejca.2019.04.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
491 Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, Otsuka A, Yamasaki T, Saito R, Kitamura M, Kitawaki T, Hishizawa M, Kawaguchi-Sakita N, Fujii T, Taura D, Sone M, Inagaki N. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One 2019;14:e0216954. [PMID: 31086392 DOI: 10.1371/journal.pone.0216954] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 16.8] [Reference Citation Analysis]
492 Afzal MZ, Dragnev K, Sarwar T, Shirai K. Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. Lung Cancer Manag 2019;8:LMT11. [PMID: 31645894 DOI: 10.2217/lmt-2018-0016] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
493 Disis MLN. JAMA Oncology-The Year in Review, 2018. JAMA Oncol 2019;5:609-10. [PMID: 30896747 DOI: 10.1001/jamaoncol.2019.0231] [Reference Citation Analysis]
494 Koyama J, Horiike A, Yoshizawa T, Dotsu Y, Ariyasu R, Saiki M, Sonoda T, Uchibori K, Nishikawa S, Kitazono S, Yanagitani N, Ninomiya H, Ishikawa Y, Nishio M. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. J Thorac Dis 2019;11:1919-28. [PMID: 31285885 DOI: 10.21037/jtd.2019.04.102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
495 Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, Lou Y, Kottschade LA, Dong H, Mansfield AS, Manochakian R, Adjei AA, Dronca RS. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? Oncologist 2019;24:e1148-55. [PMID: 31036771 DOI: 10.1634/theoncologist.2019-0094] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 12.3] [Reference Citation Analysis]
496 Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, Zheng H, Yao C, Wang Y, Lu S. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC. J Thorac Oncol. 2019;14:1378-1389. [PMID: 31026576 DOI: 10.1016/j.jtho.2019.04.007] [Cited by in Crossref: 155] [Cited by in F6Publishing: 180] [Article Influence: 38.8] [Reference Citation Analysis]
497 Remon J, Reguart N, Auclin E, Besse B. Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy? J Thorac Oncol 2019;14:963-7. [PMID: 31027971 DOI: 10.1016/j.jtho.2019.02.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
498 Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors. Oncologist 2019;24:1128-36. [PMID: 31015312 DOI: 10.1634/theoncologist.2018-0563] [Cited by in Crossref: 80] [Cited by in F6Publishing: 92] [Article Influence: 20.0] [Reference Citation Analysis]
499 Edahiro R, Ishijima M, Kurebe H, Nishida K, Uenami T, Kanazu M, Akazawa Y, Yano Y, Mori M. Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report. Thorac Cancer 2019;10:1276-9. [PMID: 30964601 DOI: 10.1111/1759-7714.13065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
500 Petrelli F, Ghidini M, Costanzo A, Rampulla V, Varricchio A, Tomasello G. Surrogate endpoints in immunotherapy trials for solid tumors. Ann Transl Med 2019;7:154. [PMID: 31157275 DOI: 10.21037/atm.2019.03.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
501 Ishihara H, Takagi T, Kondo T, Homma C, Tachibana H, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, Ishida H, Tanabe K. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol 2019;37:355.e21-9. [PMID: 30935847 DOI: 10.1016/j.urolonc.2019.03.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 10.3] [Reference Citation Analysis]
502 Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, Park SY, Yoon HI, Hong MH, Cho BC, Kim HR. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol 2019;145:1613-23. [PMID: 30911841 DOI: 10.1007/s00432-019-02899-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
503 Oyanagi J, Koh Y, Sato K, Mori K, Teraoka S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Nakanishi M, Ueda H, Yamamoto N. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Lung Cancer 2019;132:107-13. [PMID: 31097082 DOI: 10.1016/j.lungcan.2019.03.020] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
504 Guram K, Kim SS, Wu V, Sanders PD, Patel S, Schoenberger SP, Cohen EEW, Chen SY, Sharabi AB. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Front Immunol 2019;10:491. [PMID: 30936880 DOI: 10.3389/fimmu.2019.00491] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
505 Seki M, Uruha A, Ohnuki Y, Kamada S, Noda T, Onda A, Ohira M, Isami A, Hiramatsu S, Hibino M, Nakane S, Noda S, Yutani S, Hanazono A, Yaguchi H, Takao M, Shiina T, Katsuno M, Nakahara J, Matsubara S, Nishino I, Suzuki S. Inflammatory myopathy associated with PD-1 inhibitors. J Autoimmun 2019;100:105-13. [PMID: 30862448 DOI: 10.1016/j.jaut.2019.03.005] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 12.0] [Reference Citation Analysis]
506 Rashdan S, Minna JD, Gerber DE. Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 2018;6:472-8. [PMID: 29856320 DOI: 10.1016/S2213-2600(18)30172-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 10.5] [Reference Citation Analysis]
507 Hofman P. Is the onset of adverse effects of immunotherapy always bad news for the patients…?-certainly not! Ann Transl Med 2019;7:S5. [PMID: 31032286 DOI: 10.21037/atm.2019.01.14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
508 Ozawa Y, Amano Y, Kanata K, Hasegwa H, Matsui T, Kakutani T, Koyauchi T, Tanahashi M, Niwa H, Yokomura K, Suda T. Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer. Med Oncol 2019;36:33. [PMID: 30825015 DOI: 10.1007/s12032-019-1255-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
509 Le T, Minna JD, Gerber DE. Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit? Journal of Thoracic Oncology 2019;14:332-5. [DOI: 10.1016/j.jtho.2018.12.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
510 Okawa S, Kayatani H, Fujiwara K, Ozeki T, Takada K, Iwamoto Y, Minami D, Sato K, Shibayama T. Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. Intern Med 2019;58:699-702. [PMID: 30828042 DOI: 10.2169/internalmedicine.1001-18] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
511 Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 2019;4:e000457. [PMID: 30964126 DOI: 10.1136/esmoopen-2018-000457] [Cited by in Crossref: 97] [Cited by in F6Publishing: 107] [Article Influence: 24.3] [Reference Citation Analysis]
512 Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer 2019;7:57. [PMID: 30813970 DOI: 10.1186/s40425-019-0527-y] [Cited by in Crossref: 176] [Cited by in F6Publishing: 185] [Article Influence: 44.0] [Reference Citation Analysis]
513 Nakamura A, Aiba T, Kawana S, Saito R, Toi Y, Sugawara S. A Case of Pseudoprogression in Lung Adenocarcinoma Treated with Nivolumab. JJLC 2019;59:60-65. [DOI: 10.2482/haigan.59.60] [Reference Citation Analysis]
514 Sakata Y, Kawamura K, Ichikado K, Shingu N, Yasuda Y, Eguchi Y, Anan K, Hisanaga J, Nitawaki T, Iio M, Sekido Y, Nakano A, Sakagami T. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment. Lung Cancer 2019;130:159-61. [PMID: 30885338 DOI: 10.1016/j.lungcan.2019.02.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
515 Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, Felip E. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother 2019;68:341-52. [PMID: 30725206 DOI: 10.1007/s00262-019-02310-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 14.5] [Reference Citation Analysis]
516 Hayashi H, Nakagawa K. Development of PD-1 Inhibition in Cancer Therapy: Dramatic Advances for Medical Oncology. tits 2019;24:2_25-2_29. [DOI: 10.5363/tits.24.2_25] [Reference Citation Analysis]
517 Muchnik E, Loh KP, Strawderman M, Magnuson A, Mohile SG, Estrah V, Maggiore RJ. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer. J Am Geriatr Soc 2019;67:905-12. [PMID: 30698276 DOI: 10.1111/jgs.15750] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 15.0] [Reference Citation Analysis]
518 Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondéjar R, Colomer R. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer 2019;109:21-7. [PMID: 30682533 DOI: 10.1016/j.ejca.2018.10.014] [Cited by in Crossref: 132] [Cited by in F6Publishing: 138] [Article Influence: 33.0] [Reference Citation Analysis]
519 Ramos-levi AM, Rogado J, Sanchez-torres JM, Colomer R, Marazuela M. Nivolumab-induced thyroid dysfunction in patients with lung cancer. Endocrinología, Diabetes y Nutrición (English ed ) 2019;66:26-34. [DOI: 10.1016/j.endien.2018.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
520 Otsuka T, Kimura T, Koike R, Cho H, Otozai S, Yoshii T, Yagi T, Fujii T. Clinical analysis for head and neck cancer cases treated with nivolumab in Osaka International Cancer Institute. Toukeibu Gan 2019;45:46-50. [DOI: 10.5981/jjhnc.45.46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
521 Bonanno L, Pavan A, Attili I, Pasello G, Guarneri V. Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy. Journal of Thoracic Oncology 2019;14:e5-7. [DOI: 10.1016/j.jtho.2018.08.2033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
522 Andrews SC, Davies M. The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners 2019. [DOI: 10.1007/978-3-030-16550-5_7] [Reference Citation Analysis]
523 Chikaishi W, Matsuhashi N, Takahashi T, Tanaka Y, Yamaguchi K, Yoshida K. A Case of Colon Perforation during the Treatment with an Immune Checkpoint Inhibitor. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc) 2019;80:1715-1720. [DOI: 10.3919/jjsa.80.1715] [Reference Citation Analysis]
524 Ksienski D, Wai ES, Croteau N, Fiorino L, Brooks E, Poonja Z, Fenton D, Geller G, Glick D, Lesperance M. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non–Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis. Clinical Lung Cancer 2019;20:e97-e106. [DOI: 10.1016/j.cllc.2018.09.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 12.5] [Reference Citation Analysis]
525 Saijo T, Tanaka A, Ito T, Ikeda N. A Case of Nivolumab-induced Severe Neutropenia with Stomatitis, Enteritis and Liver Dysfunction. JJLC 2018;58:996-1000. [DOI: 10.2482/haigan.58.996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
526 Okada N, Kawazoe H, Takechi K, Matsudate Y, Utsunomiya R, Zamami Y, Goda M, Imanishi M, Chuma M, Hidaka N, Sayama K, Kubo Y, Tanaka A, Ishizawa K. Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study. Clin Ther 2019;41:59-67. [PMID: 30528047 DOI: 10.1016/j.clinthera.2018.11.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 13.0] [Reference Citation Analysis]
527 Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 2019;145:479-85. [DOI: 10.1007/s00432-018-2805-3] [Cited by in Crossref: 171] [Cited by in F6Publishing: 150] [Article Influence: 34.2] [Reference Citation Analysis]
528 Suresh K, Psoter KJ, Voong KR, Shankar B, Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, Feliciano JL, Brahmer JR, Feller-Kopman D, Lerner AD, Lee H, Yarmus L, Hales RK, D'Alessio F, Danoff SK, Naidoo J. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. J Thorac Oncol 2019;14:494-502. [PMID: 30503891 DOI: 10.1016/j.jtho.2018.11.016] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 12.2] [Reference Citation Analysis]
529 Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med 2018;10:93. [PMID: 30497521 DOI: 10.1186/s13073-018-0605-7] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 17.0] [Reference Citation Analysis]
530 Matsuo N, Azuma K, Hattori S, Ohtake J, Kawahara A, Ishii H, Tokito T, Yamada K, Shibata Y, Shimokawaji T, Kondo T, Kato T, Saito H, Yamada K, Sasada T, Hoshino T. Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor: Association between soluble immune mediators and tumor responses. Int J Cancer 2019;144:1170-9. [DOI: 10.1002/ijc.31923] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
531 Kenmotsu H. 薬物療法の支持療法. JJLC 2018;58:911-913. [DOI: 10.2482/haigan.58.911] [Reference Citation Analysis]
532 Zimmermann S, Peters S, Owinokoko T, Gadgeel SM. Immune Checkpoint Inhibitors in the Management of Lung Cancer. Am Soc Clin Oncol Educ Book 2018;38:682-95. [PMID: 30231367 DOI: 10.1200/EDBK_201319] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
533 Spagnuolo A, Gridelli C. "Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not? J Thorac Dis 2018;10:S4065-8. [PMID: 30631556 DOI: 10.21037/jtd.2018.09.83] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
534 Khan S, Khan SA, Luo X, Fattah FJ, Saltarski J, Gloria-McCutchen Y, Lu R, Xie Y, Li Q, Wakeland E, Gerber DE. Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer 2019;120:63-8. [PMID: 30377338 DOI: 10.1038/s41416-018-0155-1] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 14.6] [Reference Citation Analysis]
535 Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, Yamazaki N, Kitano S, Yamamoto N, Ohe Y. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci 2018;109:3583-90. [PMID: 30230649 DOI: 10.1111/cas.13800] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 15.2] [Reference Citation Analysis]
536 Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, Boucekine M, Mascaux C, Barlesi F. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. Clin Lung Cancer. 2019;20:201-207. [PMID: 30442524 DOI: 10.1016/j.cllc.2018.10.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 90] [Article Influence: 16.0] [Reference Citation Analysis]
537 Nakahama K, Tamiya A, Isa SI, Taniguchi Y, Shiroyama T, Suzuki H, Inoue T, Tamiya M, Hirashima T, Imamura F, Atagi S. Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. In Vivo 2018;32:887-91. [PMID: 29936475 DOI: 10.21873/invivo.11324] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
538 Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging 2019;46:238-50. [PMID: 30291373 DOI: 10.1007/s00259-018-4171-4] [Cited by in Crossref: 140] [Cited by in F6Publishing: 118] [Article Influence: 28.0] [Reference Citation Analysis]
539 Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y, Hida T. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis. Lung Cancer 2018;125:212-7. [PMID: 30429022 DOI: 10.1016/j.lungcan.2018.10.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 68] [Article Influence: 12.4] [Reference Citation Analysis]
540 Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata A, Katakami N, Yokota S. Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer 2018;18:946. [PMID: 30285770 DOI: 10.1186/s12885-018-4819-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
541 Sridharan V, Rahman RM, Huang RY, Chau NG, Lorch JH, Uppaluri R, Haddad RI, Hanna GJ, Schoenfeld JD. Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma. Oral Oncology 2018;85:29-34. [DOI: 10.1016/j.oraloncology.2018.08.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
542 Menshawy A, Eltonob AA, Barkat SA, Ghanem A, Mniesy MM, Mohamed I, Abdel-maboud M, Mattar OM, Elfil M, Bahbah EI, Elgebaly A. Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials. Melanoma Research 2018;28:371-9. [DOI: 10.1097/cmr.0000000000000467] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
543 Sekine K, Kanda S, Goto Y, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Ohe Y. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Lung Cancer 2018;124:179-88. [PMID: 30268458 DOI: 10.1016/j.lungcan.2018.08.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
544 De Bock M, Hulstaert E, Kruse V, Brochez L. Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review. Case Rep Dermatol 2018;10:190-7. [PMID: 30186132 DOI: 10.1159/000491572] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
545 Danlos F, Lambotte O. Pertinence des inhibiteurs des points de contrôle immunitaire chez les patients atteints de maladie auto-immune ou inflammatoire. Med Sci (Paris) 2018;34:516-8. [DOI: 10.1051/medsci/20183406007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
546 Illouz F, Drui D, Caron P, Do Cao C. Expert opinion on thyroid complications in immunotherapy. Ann Endocrinol (Paris) 2018;79:555-61. [PMID: 30126627 DOI: 10.1016/j.ando.2018.07.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
547 Hamamoto Y. Need for prospective collection of experience and repeated samples in esophageal squamous cell carcinoma. J Thorac Dis 2018;10:S2086-8. [PMID: 30023126 DOI: 10.21037/jtd.2018.05.37] [Reference Citation Analysis]
548 Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I. Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. Oncotarget 2018;9:30587-93. [PMID: 30093971 DOI: 10.18632/oncotarget.25743] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
549 Johnson DB. Toxicities and outcomes: Do steroids matter? Cancer 2018;124:3638-40. [PMID: 29975416 DOI: 10.1002/cncr.31627] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
550 KENJI NAKAHAMA, AKIHIRO TAMIYA, SHUN-ICHI ISA, YOSHIHIKO TANIGUCHI, TAKAYUKI SHIROYAMA, HIDEKAZU SUZUKI, TAKAKO INOUE, MOTOHIRO TAMIYA, TOMONORI HIRASHIMA, FUMIO IMAMURA, SHINJI ATAGI. Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. In Vivo 2018;32. [PMID: 29936475 DOI: 10.21873/invivo.112324] [Reference Citation Analysis]
551 Haratani K, Hayashi H, Nakagawa K. Immune-Related Adverse Events-A Novel Prediction of Nivolumab Efficacy?-Reply. JAMA Oncol 2018;4:1017-8. [PMID: 29852041 DOI: 10.1001/jamaoncol.2018.0751] [Reference Citation Analysis]
552 Cheng Y, Wu Y, Wu L. Immune-Related Adverse Events—A Novel Prediction of Nivolumab Efficacy? JAMA Oncol 2018;4:1017. [DOI: 10.1001/jamaoncol.2018.0745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
553 Milano G, Innocenti F, Lacarelle B, Ciccolini J. “No pain, No gain” still true with immunotherapy: When the finger shows the moon, look at the moon! Critical Reviews in Oncology/Hematology 2018;127:1-5. [DOI: 10.1016/j.critrevonc.2018.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
554 Arays R, Wang P. A case of pembrolizumab-induced localized organizing pneumonia. Scand J Immunol 2018;88:e12677. [DOI: 10.1111/sji.12677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
555 頭頸部がんにおける免疫チェックポイント阻害薬の適応と実際. Nippon Jibiinkoka Gakkai Kaiho 2018;121:826-828. [DOI: 10.3950/jibiinkoka.121.826] [Reference Citation Analysis]
556 Tiu AC, Potdar R, Djibo DA, Masab M, Dourado C. Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center. Med Oncol 2018;35:109. [PMID: 29915891 DOI: 10.1007/s12032-018-1171-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
557 Ramos-Levi AM, Rogado J, Sanchez-Torres JM, Colomer R, Marazuela M. Nivolumab-induced thyroid dysfunction in patients with lung cancer. Endocrinol Diabetes Nutr (Engl Ed) 2019;66:26-34. [PMID: 29910159 DOI: 10.1016/j.endinu.2018.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
558 Nivolumab. Reactions Weekly 2018;1707:211-211. [DOI: 10.1007/s40278-018-48027-3] [Reference Citation Analysis]
559 Facchinetti F, Gnetti L, Caruana P, Fornaroli F, Luigi de'Angelis G, Sabato M, Ferri L, Cosenza A, Bordi P, Tiseo M. Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient. Clin Lung Cancer 2018;19:e591-6. [PMID: 29801705 DOI: 10.1016/j.cllc.2018.04.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
560 Remon J, Mezquita L, Corral J, Vilariño N, Reguart N. Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. J Thorac Dis 2018;10:S1516-33. [PMID: 29951303 DOI: 10.21037/jtd.2017.12.52] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
561 Nakatani Y, Kawakami H, Ichikawa M, Yamamoto S, Otsuka Y, Mashiko A, Takashima Y, Ito A, Nakagawa K, Arima S. Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer. Invest New Drugs 2018;36:726-31. [DOI: 10.1007/s10637-018-0596-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
562 Hakozaki T, Okuma Y, Kashima J. Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report. BMC Cancer 2018;18:302. [PMID: 29554874 DOI: 10.1186/s12885-018-4212-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
563 Mitsune A, Yanagisawa S, Fukuhara T, Miyauchi E, Morita M, Ono M, Tojo Y, Ichinose M. Relapsed Myasthenia Gravis after Nivolumab Treatment. Intern Med 2018;57:1893-7. [PMID: 29434145 DOI: 10.2169/internalmedicine.9153-17] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
564 Kiyota N. Immune check point inhibitors for head and neck cancer. Toukeibu Gan 2018;44:336-341. [DOI: 10.5981/jjhnc.44.336] [Reference Citation Analysis]
565 Naime FF. Pericardial Effusion with Tamponade, an Immune-Related Adverse Event Associated with Nivolumab Therapy: A Case Report and Review of the Literature. JCT 2018;09:1039-1047. [DOI: 10.4236/jct.2018.912085] [Reference Citation Analysis]
566 Kiyota N. Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program. Journal of Japan Society for Oral Tumors 2018;30:144-150. [DOI: 10.5843/jsot.30.144] [Reference Citation Analysis]
567 Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 2018;115:71-4. [DOI: 10.1016/j.lungcan.2017.11.019] [Cited by in Crossref: 233] [Cited by in F6Publishing: 249] [Article Influence: 46.6] [Reference Citation Analysis]
568 Ornstein MC, Garcia JA. Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review. Kidney Cancer 2017;1:133-41. [PMID: 30334015 DOI: 10.3233/KCA-170017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
569 Zhai X, Zhang J, Tian Y, Li J, Jing W, Guo H, Zhu H. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biol Med 2020;17:599-611. [PMID: 32944393 DOI: 10.20892/j.issn.2095-3941.2020.0102] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Reference Citation Analysis]